Nutritional	O
supplements	O
with	O
oral	O
amino	O
acid	O
mixtures	O
increases	O
whole	O
-	O
body	O
lean	O
mass	O
and	O
insulin	O
sensitivity	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

Decreases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
can	O
cause	O
sarcopenia	B
,	O
a	O
disease	O
frequently	O
found	O
in	O
the	O
elderly	O
.	O

This	O
condition	O
is	O
frequently	O
associated	O
with	O
frailty	B
and	O
disability	B
in	I
aging	I
as	O
well	O
as	O
the	O
onset	O
and	O
progression	O
of	O
several	O
geriatric	B
syndromes	I
.	O

Sarcopenia	B
therefore	O
must	O
be	O
managed	O
with	O
multidimensional	O
approaches	O
that	O
include	O
physical	O
training	O
,	O
nutritional	O
support	O
,	O
and	O
metabolic	O
and	O
anabolic	O
treatment	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
an	O
orally	O
administered	O
special	O
mixture	O
of	O
amino	O
acids	O
(	O
AAs	O
)	O
in	O
elderly	O
subjects	O
with	O
reduced	O
lean	O
body	O
mass	O
and	O
sarcopenia	B
.	O

A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
was	O
conducted	O
in	O
41	O
elderly	O
subjects	O
(	O
age	O
range	O
:	O
66	O
-	O
84	O
years	O
)	O
with	O
sarcopenia	B
,	O
assigned	O
to	O
2	O
distinct	O
treatments	O
(	O
AAs	O
and	O
placebo	O
)	O
.	O

All	O
subjects	O
had	O
normal	O
body	O
weight	O
(	O
body	O
mass	O
index	O
within	O
19	O
-	O
23	O
)	O
.	O

The	O
AA	O
treatment	O
consisted	O
of	O
70.6	O
kcal	O
/	O
day	O
(	O
1	O
kcal	O
=	O
4.2	O
kJ	O
)	O
of	O
8	O
g	O
of	O
essential	O
AA	O
snacks	O
,	O
given	O
at	O
10	O
:	O
00	O
am	O
and	O
5	O
:	O
00	O
pm	O
.	O

Lean	O
mass	O
was	O
measured	O
with	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
in	O
leg	O
,	O
arm	O
,	O
and	O
trunk	O
tissues	O
.	O

Significant	O
increases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
all	O
areas	O
were	O
seen	O
after	O
6	O
months	O
and	O
more	O
consistently	O
after	O
18	O
months	O
of	O
oral	O
nutritional	O
supplementation	O
with	O
AAs	O
.	O

Fasting	O
blood	O
glucose	O
,	O
serum	O
insulin	O
,	O
and	O
homeostatic	O
model	O
assessment	O
of	O
insulin	B
resistance	I
(	O
an	O
index	O
of	O
insulin	B
resistance	I
)	O
significantly	O
decreased	O
during	O
AA	O
treatment	O
.	O

Furthermore	O
,	O
a	O
significant	O
reduction	O
in	O
serum	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
a	O
significant	O
increase	O
in	O
both	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
serum	O
concentrations	O
and	O
in	O
the	O
IGF	O
-	O
1	O
/	O
TNF	O
-	O
alpha	O
ratio	O
were	O
also	O
found	O
.	O

No	O
significant	O
adverse	O
effects	O
were	O
observed	O
during	O
AA	O
treatment	O
.	O

These	O
preliminary	O
data	O
indicate	O
that	O
nutritional	O
supplements	O
with	O
the	O
oral	O
AA	O
mixture	O
significantly	O
increased	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

The	O
improvement	O
in	O
the	O
amount	O
of	O
whole	O
-	O
body	O
lean	O
mass	O
could	O
be	O
linked	O
to	O
increased	O
insulin	O
sensitivity	O
and	O
anabolic	O
conditions	O
related	O
to	O
IGF	O
-	O
1	O
availability	O
.	O

Variable	O
response	O
to	O
opioid	O
treatment	O
:	O
any	O
genetic	O
predictors	O
within	O
sight	O
?	O

The	O
aim	O
of	O
this	O
literature	O
review	O
is	O
to	O
summarize	O
and	O
discuss	O
the	O
available	O
evidence	O
for	O
a	O
relationship	O
between	O
polymorphisms	O
in	O
human	O
genes	O
and	O
variability	O
in	O
opioid	O
analgesia	O
and	O
side	O
effects	O
among	O
patients	O
treated	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

The	O
evidence	O
supporting	O
a	O
role	O
of	O
certain	O
alleles	O
,	O
genotypes	O
or	O
haplotypes	O
in	O
modulation	O
of	O
opioid	O
analgesia	O
is	O
derived	O
from	O
a	O
limited	O
number	O
of	O
studies	O
,	O
a	O
limited	O
number	O
of	O
genes	O
and	O
a	O
limited	O
number	O
of	O
opioids	O
.	O

Although	O
several	O
interesting	O
candidates	O
have	O
emerged	O
as	O
potentially	O
relevant	O
factors	O
,	O
only	O
for	O
one	O
polymorphism	O
,	O
the	O
prevalent	O
118A	O
>	O
G	O
of	O
the	O
micro	O
-	O
opioid	O
receptor	O
,	O
the	O
accumulated	O
evidence	O
is	O
sufficient	O
to	O
suggest	O
a	O
clinically	O
relevant	O
effect	O
for	O
an	O
opioid	O
used	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

Still	O
the	O
data	O
are	O
valid	O
only	O
at	O
the	O
group	O
level	O
and	O
can	O
not	O
be	O
used	O
to	O
predict	O
treatment	O
outcome	O
in	O
individual	O
patients	O
.	O

Only	O
a	O
few	O
of	O
the	O
symptoms	O
often	O
seen	O
as	O
opioid	O
adverse	O
effects	O
in	O
palliative	O
care	O
,	O
such	O
as	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
and	O
sedation	B
,	O
have	O
been	O
associated	O
with	O
genetic	O
variants	O
in	O
various	O
genes	O
,	O
but	O
the	O
results	O
have	O
been	O
based	O
on	O
case	O
reports	O
,	O
healthy	O
volunteers	O
or	O
post	O
-	O
operative	O
patients	O
.	O

So	O
far	O
,	O
there	O
is	O
no	O
clear	O
evidence	O
that	O
genetic	O
markers	O
can	O
be	O
used	O
to	O
predict	O
opioid	O
efficacy	O
or	O
adverse	O
effects	O
in	O
palliative	O
care	O
patients	O
.	O

This	O
reflects	O
the	O
general	O
lack	O
of	O
studies	O
performed	O
in	O
the	O
context	O
of	O
palliative	O
care	O
,	O
the	O
lack	O
of	O
sufficiently	O
scaled	O
studies	O
and	O
the	O
lack	O
of	O
international	O
standards	O
for	O
the	O
assessment	O
of	O
subjective	O
symptoms	O
.	O

Design	O
of	O
potent	O
,	O
non	O
-	O
toxic	O
antimicrobial	O
agents	O
based	O
upon	O
the	O
naturally	O
occurring	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
and	O
peptide	O
XT	O
-	O
7	O
.	O

The	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
(	O
GFKDLLKGAAKALVKTVLF	O
.	O

NH	O
(	O
2	O
)	O
)	O
and	O
XT	O
-	O
7	O
(	O
GLLGPLLKIAAKVGSNLL	O
.	O

NH	O
(	O
2	O
)	O
)	O
,	O
show	O
broad	O
-	O
spectrum	O
antimicrobial	O
activity	O
but	O
their	O
therapeutic	O
potential	O
is	O
limited	O
by	O
toxicity	O
against	O
mammalian	O
cells	O
.	O

Circular	O
dichroism	O
spectra	O
demonstrate	O
that	O
the	O
peptides	O
adopt	O
an	O
amphipathic	O
alpha	O
-	O
helical	O
conformation	O
in	O
a	O
membrane	O
-	O
mimetic	O
solvent	O
.	O

This	O
study	O
has	O
investigated	O
the	O
cytolytic	O
properties	O
of	O
analogs	O
containing	O
selected	O
amino	O
acid	O
substitutions	O
that	O
increase	O
cationicity	O
while	O
maintaining	O
amphipathicity	O
.	O

Substitutions	O
at	O
Ala	O
(	O
10	O
)	O
,	O
Val	O
(	O
14	O
)	O
,	O
and	O
Leu	O
(	O
18	O
)	O
in	O
ascaphin	O
-	O
8	O
by	O
either	O
L	O
-	O
Lys	O
or	O
D	O
-	O
Lys	O
produced	O
peptides	O
that	O
retained	O
antimicrobial	O
activity	O
against	O
the	O
bacteria	O
Escherichia	O
coli	O
and	O
Staphylococcus	O
aureus	O
and	O
the	O
opportunistic	O
yeast	O
pathogen	O
,	O
Candida	O
albicans	O
but	O
showed	O
appreciably	O
reduced	O
toxicities	O
(	O
>	O
10	O
-	O
fold	O
)	O
against	O
human	O
erythrocytes	O
,	O
HepG2	O
hepatoma	O
-	O
derived	O
cells	O
,	O
and	O
L929	O
fibroblasts	O
.	O

The	O
improved	O
therapeutic	O
index	O
of	O
the	O
L	O
-	O
Lys	O
(	O
18	O
)	O
and	O
D	O
-	O
Lys	O
(	O
18	O
)	O
analogs	O
correlated	O
with	O
a	O
decrease	O
in	O
%	O
helicity	O
and	O
in	O
effective	O
hydrophobicity	O
.	O

Substitution	O
of	O
Gly	O
(	O
4	O
)	O
by	O
L	O
-	O
Lys	O
in	O
XT	O
-	O
7	O
produced	O
an	O
analog	O
with	O
high	O
potency	O
against	O
micro	O
-	O
organisms	O
(	O
MIC	O
<	O
or	O
=	O
25	O
microM	O
)	O
but	O
low	O
cytolytic	O
activity	O
against	O
erythrocytes	O
(	O
LD	O
(	O
50	O
)	O
>	O
500	O
microM	O
)	O
and	O
this	O
increase	O
in	O
therapeutic	O
index	O
also	O
correlated	O
with	O
decreased	O
helicity	O
and	O
hydrophobicity	O
.	O

Analogs	O
of	O
XT	O
-	O
7	O
with	O
increased	O
cationicity	O
,	O
containing	O
multiple	O
substitutions	O
by	O
L	O
-	O
Lys	O
,	O
not	O
only	O
displayed	O
increased	O
antimicrobial	O
potencies	O
,	O
particularly	O
against	O
Candida	O
albicans	O
(	O
MIC	O
<	O
or	O
=	O
6	O
microM	O
)	O
,	O
but	O
also	O
increased	O
hemolytic	O
activities	O
.	O

The	O
role	O
of	O
placental	O
breast	O
cancer	O
resistance	O
protein	O
in	O
the	O
efflux	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

Gestational	B
diabetes	I
mellitus	I
is	O
a	O
common	O
medical	O
complication	O
in	O
pregnancy	O
.	O

Recent	O
findings	O
demonstrate	O
that	O
glyburide	O
is	O
effluxed	O
against	O
a	O
concentration	O
gradient	O
from	O
the	O
fetal	O
to	O
the	O
maternal	O
circulation	O
.	O

However	O
,	O
the	O
transport	O
systems	O
involved	O
in	O
the	O
active	O
efflux	O
of	O
glyburide	O
in	O
the	O
human	O
placenta	O
have	O
not	O
yet	O
been	O
identified	O
.	O

The	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
,	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
)	O
,	O
is	O
highly	O
expressed	O
in	O
placental	O
syncytiotrophoblast	O
suggesting	O
it	O
may	O
play	O
a	O
role	O
in	O
protecting	O
the	O
fetus	O
from	O
drug	B
toxicity	I
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
BCRP	O
participates	O
in	O
the	O
transport	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

The	O
placental	O
transfer	O
of	O
glyburide	O
in	O
the	O
presence	O
of	O
specific	O
BCRP	O
inhibitor	O
,	O
nicardipine	O
,	O
was	O
investigated	O
using	O
the	O
ex	O
vivo	O
dual	O
perfusion	O
system	O
of	O
isolated	O
human	O
placental	O
lobules	O
.	O

In	O
a	O
closed	O
experiment	O
,	O
glyburide	O
was	O
added	O
(	O
200	O
ng	O
/	O
mL	O
)	O
to	O
the	O
maternal	O
and	O
fetal	O
circulations	O
and	O
the	O
BCRP	O
inhibitor	O
(	O
20	O
microM	O
)	O
was	O
added	O
to	O
the	O
maternal	O
circulation	O
.	O

Samples	O
were	O
taken	O
during	O
pre	O
-	O
control	O
,	O
experimental	O
,	O
and	O
post	O
-	O
control	O
periods	O
for	O
measurement	O
of	O
glyburide	O
and	O
markers	O
of	O
tissue	O
viability	O
.	O

Results	O
obtained	O
from	O
perfusions	O
(	O
n	O
=	O
4	O
)	O
in	O
the	O
presence	O
of	O
the	O
BCRP	O
inhibitor	O
show	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
fetal	O
-	O
to	O
-	O
maternal	O
concentration	O
ratio	O
of	O
glyburide	O
determined	O
at	O
180	O
min	O
,	O
0.56	O
+	O
/	O
-	O
0.06	O
,	O
when	O
compared	O
to	O
the	O
mean	O
ratio	O
obtained	O
in	O
the	O
absence	O
of	O
inhibitor	O
,	O
0.32	O
+	O
/	O
-	O
0.06	O
(	O
p	O
=	O
0.04	O
)	O
.	O

These	O
data	O
indicate	O
that	O
nicardipine	O
partially	O
blocked	O
the	O
transfer	O
of	O
glyburide	O
across	O
the	O
whole	O
placenta	O
through	O
its	O
inhibition	O
of	O
BCRP	O
.	O

This	O
is	O
the	O
first	O
ex	O
vivo	O
evidence	O
that	O
BCRP	O
actively	O
transports	O
glyburide	O
.	O

The	O
efficacy	O
of	O
Femal	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
study	O
.	O

INTRODUCTION	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomised	O
,	O
parallel	O
-	O
group	O
,	O
multicentre	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
pollen	O
-	O
based	O
herbal	O
medicinal	O
product	O
,	O
Femal	O
(	O
Sea	O
-	O
Band	O
Ltd	O
,	O
Leicestershire	O
,	O
UK	O
)	O
,	O
on	O
premenstrual	B
sleep	I
disturbances	I
(	O
PSD	B
)	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
(	O
PMS	B
)	O
.	O

METHODS	O
:	O
Femal	O
,	O
160	O
mg	O
twice	O
-	O
daily	O
,	O
was	O
given	O
for	O
four	O
menstrual	O
cycles	O
to	O
50	O
women	O
,	O
and	O
placebo	O
to	O
51	O
women	O
.	O

PSD	B
were	O
evaluated	O
on	O
a	O
visual	O
analogue	O
scale	O
prior	O
to	O
and	O
after	O
the	O
four	O
cycles	O
.	O

The	O
effect	O
on	O
overall	O
PMS	B
symptoms	I
was	O
assessed	O
with	O
the	O
Steiner	O
premenstrual	B
tension	I
syndrome	I
(	O
PMTS	B
)	O
self	O
-	O
rating	O
questionnaire	O
.	O

The	O
results	O
were	O
analysed	O
statistically	O
based	O
on	O
intention	O
to	O
treat	O
.	O

RESULTS	O
:	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
PSD	B
(	O
P	O
<	O
0.05	O
)	O
whereas	O
placebo	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
.	O

In	O
a	O
subgroup	O
analysis	O
of	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
the	O
reduction	O
of	O
PSD	B
was	O
even	O
more	O
pronounced	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
overall	O
degree	O
of	O
PMS	B
symptom	I
reduction	O
between	O
Femal	O
and	O
placebo	O
when	O
all	O
participating	O
women	O
were	O
evaluated	O
(	O
P	O
>	O
0.05	O
)	O
.	O

However	O
,	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
Steiner	O
score	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
frequency	O
of	O
adverse	O
events	O
was	O
not	O
significantly	O
different	O
in	O
women	O
on	O
Femal	O
compared	O
to	O
women	O
on	O
placebo	O
(	O
P	O
>	O
0.05	O
)	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
recorded	O
.	O

CONCLUSION	O
:	O
Femal	O
treatment	O
reduced	O
PSD	B
to	O
a	O
significant	O
degree	O
,	O
particularly	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
.	O

Femal	O
treatment	O
also	O
reduced	O
overall	O
PMS	B
symptoms	I
in	O
women	O
with	O
irritability	B
(	O
but	O
not	O
dysphoria	B
)	O
as	O
their	O
main	O
PMS	B
symptom	I
.	O

The	O
safety	O
of	O
Femal	O
and	O
its	O
efficacy	O
in	O
PSD	B
and	O
other	O
symptoms	O
in	O
women	O
with	O
irritability	B
as	O
the	O
main	O
symptom	O
cluster	O
makes	O
this	O
herbal	O
medicinal	O
product	O
a	O
promising	O
addition	O
to	O
the	O
therapeutic	O
arsenal	O
for	O
women	O
with	O
PMS	B
.	O

A	O
novel	O
polyherbal	O
microbicide	O
with	O
inhibitory	O
effect	O
on	O
bacterial	O
,	O
fungal	O
and	O
viral	O
genital	O
pathogens	O
.	O

A	O
polyherbal	O
cream	O
(	O
Basant	O
)	O
has	O
been	O
formulated	O
using	O
diferuloylmethane	O
(	O
curcumin	O
)	O
,	O
purified	O
extracts	O
of	O
Emblica	O
officinalis	O
(	O
Amla	O
)	O
,	O
purified	O
saponins	O
from	O
Sapindus	O
mukorossi	O
,	O
Aloe	O
vera	O
and	O
rose	O
water	O
along	O
with	O
pharmacopoeially	O
approved	O
excipients	O
and	O
preservatives	O
.	O

Basant	O
inhibits	O
the	O
growth	O
of	O
WHO	O
strains	O
and	O
clinical	O
isolates	O
of	O
Neisseria	O
gonorrhoeae	O
,	O
including	O
those	O
resistant	O
to	O
penicillin	O
,	O
tetracycline	O
,	O
nalidixic	O
acid	O
and	O
ciprofloxacin	O
.	O

It	O
has	O
pronounced	O
inhibitory	O
action	O
against	O
Candida	O
glabrata	O
,	O
Candida	O
albicans	O
and	O
Candida	O
tropicalis	O
isolated	O
from	O
women	O
with	O
vulvovaginal	B
candidiasis	I
,	O
including	O
three	O
isolates	O
resistant	O
to	O
azole	O
drugs	O
and	O
amphotericin	O
B	O
.	O

Basant	O
displayed	O
a	O
high	O
virucidal	O
action	O
against	O
human	O
immunodeficiency	O
virus	O
HIV	O
-	O
1NL4	O
.3	O
in	O
CEM	O
-	O
GFP	O
reporter	O
T	O
and	O
P4	O
(	O
Hela	O
-	O
CD4	O
-	O
LTR	O
-	O
betaGal	O
)	O
cell	O
lines	O
with	O
a	O
50	O
%	O
effective	O
concentration	O
(	O
EC50	O
)	O
of	O
1	O
:	O
20000	O
dilution	O
and	O
nearly	O
complete	O
(	O
98	O
-	O
99	O
%	O
)	O
inhibition	O
at	O
1	O
:	O
1000	O
dilution	O
.	O

It	O
also	O
prevented	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
virus	O
into	O
P4	O
-	O
CCR5	O
cells	O
(	O
EC50	O
approximately	O
1	O
:	O
2492	O
)	O
.	O

Two	O
ingredients	O
,	O
Aloe	O
and	O
Amla	O
,	O
inhibited	O
the	O
transduction	O
of	O
human	O
papillomavirus	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
pseudovirus	O
in	O
HeLa	O
cells	O
at	O
concentrations	O
far	O
below	O
those	O
that	O
are	O
cytotoxic	O
and	O
those	O
used	O
in	O
the	O
formulation	O
.	O

Basant	O
was	O
found	O
to	O
be	O
totally	O
safe	O
according	O
to	O
pre	O
-	O
clinical	O
toxicology	O
carried	O
out	O
on	O
rabbit	O
vagina	O
after	O
application	O
for	O
7	O
consecutive	O
days	O
or	O
twice	O
daily	O
for	O
3	O
weeks	O
.	O

Basant	O
has	O
the	O
potential	O
of	O
regressing	O
vulvovaginal	B
candidiasis	I
and	O
preventing	O
N	O
.	O

gonorrhoeae	O
,	O
HIV	O
and	O
HPV	B
infections	I
.	O

Neuroprotection	O
by	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
phycocyanin	O
against	O
iron	O
-	O
induced	O
toxicity	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
the	O
biliprotein	O
phycocyanin	O
isolated	O
from	O
this	O
microalga	O
,	O
on	O
the	O
activities	O
of	O
the	O
antioxidant	O
enzymes	O
SOD	O
,	O
CAT	O
,	O
GPx	O
,	O
and	O
GR	O
,	O
lipid	O
peroxidation	O
inhibitory	O
activity	O
and	O
glutathione	O
levels	O
after	O
the	O
iron	O
induced	O
oxidative	O
stress	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Iron	O
is	O
one	O
of	O
the	O
most	O
important	O
agents	O
that	O
produce	O
oxidative	O
stress	O
and	O
decline	O
of	O
neuronal	O
functions	O
.	O

S	O
.	O

platensis	O
protean	O
extract	O
and	O
phycocyanin	O
exert	O
the	O
antioxidant	O
activity	O
by	O
protecting	O
the	O
activity	O
of	O
the	O
cellular	O
antioxidant	O
enzymes	O
total	O
GPx	O
,	O
GPx	O
-	O
Se	O
and	O
GR	O
and	O
by	O
increasing	O
reduced	O
glutathione	O
in	O
cells	O
against	O
oxidative	O
stress	O
induced	O
by	O
iron	O
.	O

These	O
results	O
suggested	O
that	O
S	O
.	O

platensis	O
protean	O
extract	O
is	O
a	O
powerful	O
antioxidant	O
through	O
a	O
mechanism	O
related	O
to	O
antioxidant	O
activity	O
,	O
capable	O
of	O
interfering	O
with	O
radical	O
-	O
mediated	O
cell	O
death	O
.	O

S	O
.	O

platensis	O
may	O
be	O
useful	O
in	O
diseases	O
known	O
to	O
be	O
aggravated	O
by	O
reactive	O
oxygen	O
species	O
and	O
in	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
neurodegenerative	B
disorders	I
as	O
long	O
as	O
iron	O
has	O
been	O
implicated	O
in	O
the	O
neuropathology	O
of	O
several	O
neurodegenerative	B
disorders	I
such	O
as	O
Alzheimer	O
's	O
or	O
Parkinson	B
diseases	I
.	O

Safety	O
and	O
pharmacodynamics	O
of	O
lansoprazole	O
in	O
patients	O
with	O
gastroesophageal	B
reflux	I
disease	I
aged	O
<	O
1	O
year	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
proton	O
pump	O
inhibitors	O
(	O
PPIs	O
)	O
for	O
the	O
treatment	O
of	O
gastroesophageal	B
reflux	I
disease	I
(	O
GERD	B
)	O
in	O
pediatric	O
patients	O
<	O
1	O
year	O
of	O
age	O
is	O
increasing	O
.	O

However	O
,	O
few	O
studies	O
with	O
PPIs	O
have	O
been	O
reported	O
in	O
such	O
patients	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
once	O
-	O
daily	O
lansoprazole	O
on	O
safety	O
and	O
to	O
characterize	O
the	O
pharmacodynamic	O
profile	O
of	O
lansoprazole	O
in	O
a	O
subset	O
of	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

The	O
effect	O
of	O
lansoprazole	O
on	O
predefined	O
GERD	B
-	I
associated	I
symptoms	I
was	O
also	O
assessed	O
.	O

METHODS	O
:	O
Two	O
phase	O
I	O
,	O
single	O
-	O
and	O
repeated	O
-	O
dose	O
,	O
randomized	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
multicenter	O
studies	O
were	O
performed	O
.	O

Both	O
studies	O
involved	O
either	O
a	O
7	O
-	O
or	O
14	O
-	O
day	O
pre	O
-	O
treatment	O
period	O
,	O
with	O
a	O
dose	O
administration	O
period	O
of	O
5	O
days	O
,	O
and	O
a	O
follow	O
-	O
up	O
period	O
of	O
30	O
days	O
for	O
adverse	O
events	O
collection	O
.	O

A	O
total	O
of	O
six	O
investigative	O
sites	O
were	O
involved	O
:	O
four	O
university	O
hospital	O
/	O
medical	O
centers	O
(	O
three	O
in	O
Poland	O
,	O
one	O
in	O
the	O
US	O
)	O
,	O
one	O
large	O
regional	O
medical	O
center	O
(	O
Poland	O
)	O
,	O
and	O
one	O
private	O
practice	O
(	O
US	O
)	O
.	O

The	O
studies	O
involved	O
24	O
neonates	O
(	O
<	O
or	O
=	O
28	O
days	O
of	O
age	O
)	O
and	O
24	O
infants	O
(	O
>	O
28	O
days	O
but	O
<	O
1	O
year	O
of	O
age	O
)	O
with	O
GERD	O
-	O
associated	O
symptoms	O
diagnosed	O
by	O
medical	O
history	O
and	O
the	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
.	O

Eligible	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
lansoprazole	O
0.5	O
or	O
1.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
neonates	O
)	O
,	O
or	O
1.0	O
or	O
2.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
infants	O
)	O
,	O
for	O
5	O
days	O
.	O

Safety	O
and	O
pharmacodynamic	O
parameters	O
were	O
the	O
primary	O
outcome	O
measures	O
.	O

Safety	O
and	O
GERD	B
symptoms	I
were	O
assessed	O
in	O
all	O
participants	O
.	O

Intragastric	O
/	O
intraesophageal	O
pH	O
monitoring	O
was	O
performed	O
in	O
a	O
subset	O
of	O
six	O
neonates	O
and	O
six	O
infants	O
at	O
baseline	O
and	O
on	O
dose	O
administration	O
days	O
1	O
and	O
5	O
.	O

RESULTS	O
:	O
Over	O
5	O
days	O
of	O
daily	O
dose	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
in	O
neonates	O
and	O
infants	O
.	O

Four	O
neonates	O
and	O
one	O
infant	O
experienced	O
mild	O
to	O
moderate	O
treatment	O
-	O
related	O
adverse	O
events	O
during	O
the	O
dose	O
administration	O
period	O
.	O

One	O
neonate	O
experienced	O
a	O
serious	O
adverse	O
event	O
that	O
was	O
unrelated	O
to	O
treatment	O
.	O

Lansoprazole	O
increased	O
the	O
percentage	O
of	O
time	O
that	O
intragastric	O
pH	O
was	O
above	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
over	O
the	O
24	O
-	O
hour	O
post	O
-	O
dose	O
period	O
on	O
days	O
1	O
and	O
5	O
when	O
compared	O
with	O
baseline	O
.	O

Mean	O
24	O
-	O
hour	O
integrated	O
gastric	O
acidity	O
decreased	O
from	O
baseline	O
to	O
day	O
5	O
in	O
both	O
populations	O
.	O

The	O
daily	O
number	O
of	O
episodes	O
of	O
regurgitation	B
/	O
vomiting	B
was	O
lower	O
than	O
at	O
baseline	O
among	O
neonates	O
after	O
5	O
days	O
of	O
lansoprazole	O
treatment	O
;	O
among	O
infants	O
,	O
both	O
the	O
prevalence	O
and	O
the	O
average	O
daily	O
number	O
of	O
episodes	O
of	O
several	O
individual	O
GERD	B
-	I
associated	I
symptoms	I
were	O
lower	O
than	O
at	O
baseline	O
.	O

CONCLUSIONS	O
:	O
After	O
5	O
days	O
of	O
open	O
-	O
label	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
and	O
increased	O
intragastric	O
pH	O
in	O
pediatric	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

A	O
decrease	O
in	O
the	O
frequency	O
of	O
GERD	B
symptoms	I
was	O
also	O
observed	O
.	O

Low	O
-	O
dose	O
interleukin	O
-	O
2	O
immunotherapy	O
does	O
not	O
improve	O
outcome	O
of	O
patients	O
age	O
60	O
years	O
and	O
older	O
with	O
acute	B
myeloid	I
leukemia	I
in	O
first	O
complete	O
remission	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
Study	O
9720	O
.	O

PURPOSE	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
(	O
CALGB	O
)	O
9720	O
evaluated	O
subcutaneous	O
low	O
-	O
dose	O
recombinant	O
interleukin	O
-	O
2	O
(	O
rIL	O
-	O
2	O
)	O
maintenance	O
immunotherapy	O
as	O
a	O
strategy	O
for	O
prolonging	O
remission	O
in	O
older	O
patients	O
with	O
acute	B
myeloid	I
leukemia	I
(	O
AML	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
AML	B
patients	O
age	O
60	O
years	O
and	O
older	O
in	O
first	O
complete	O
remission	O
after	O
induction	O
and	O
consolidation	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
no	O
further	O
therapy	O
or	O
a	O
90	O
-	O
day	O
regimen	O
of	O
14	O
-	O
day	O
cycles	O
of	O
low	O
-	O
dose	O
rIL	O
-	O
2	O
,	O
aimed	O
at	O
expanding	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
followed	O
by	O
3	O
-	O
day	O
higher	O
doses	O
aimed	O
at	O
activating	O
cytotoxicity	O
of	O
expanded	O
NK	O
cells	O
to	O
lyse	O
residual	O
AML	O
cells	O
.	O

All	O
randomly	O
assigned	O
patients	O
were	O
included	O
in	O
an	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
163	O
(	O
64	O
%	O
)	O
of	O
254	O
patients	O
who	O
completed	O
induction	O
and	O
consolidation	O
chemotherapy	O
on	O
CALGB	O
9720	O
were	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
(	O
n	O
=	O
81	O
)	O
or	O
no	O
further	O
therapy	O
(	O
n	O
=	O
82	O
)	O
;	O
the	O
most	O
common	O
reasons	O
for	O
lack	O
of	O
random	O
assignment	O
were	O
patient	O
refusal	O
and	O
relapse	O
.	O

Fifteen	O
patients	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
never	O
initiated	O
it	O
because	O
of	O
refusal	O
,	O
intercurrent	O
medical	O
problems	O
,	O
or	O
relapse	O
,	O
and	O
24	O
patients	O
initiated	O
rIL	O
-	O
2	O
but	O
stopped	O
early	O
because	O
of	O
toxicity	O
or	O
relapse	O
.	O

Grade	O
4	O
toxicities	O
during	O
rIL	O
-	O
2	O
therapy	O
included	O
thrombocytopenia	B
(	O
65	O
%	O
)	O
and	O
neutropenia	B
(	O
64	O
%	O
)	O
,	O
and	O
grade	O
3	O
toxicities	O
included	O
anemia	B
(	O
33	O
%	O
)	O
,	O
infection	B
(	O
24	O
%	O
)	O
and	O
malaise	B
/	O
fatigue	B
(	O
14	O
%	O
)	O
.	O

Forty	O
-	O
two	O
patients	O
(	O
52	O
%	O
)	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
completed	O
the	O
full	O
90	O
-	O
day	O
course	O
.	O

Patients	O
in	O
both	O
arms	O
had	O
similar	O
distributions	O
of	O
both	O
disease	O
-	O
free	O
(	O
combined	O
median	O
=	O
6.1	O
months	O
;	O
P	O
=	O
.47	O
)	O
and	O
overall	O
survival	O
(	O
combined	O
median	O
=	O
14.7	O
months	O
;	O
P	O
=	O
.61	O
)	O
after	O
random	O
assignment	O
.	O

Moreover	O
,	O
the	O
42	O
patients	O
who	O
completed	O
all	O
planned	O
therapy	O
did	O
not	O
show	O
prolongation	O
of	O
disease	O
-	O
free	O
or	O
overall	O
survival	O
.	O

CONCLUSION	O
:	O
Low	O
-	O
dose	O
rIL	O
-	O
2	O
maintenance	O
immunotherapy	O
is	O
not	O
a	O
successful	O
strategy	O
in	O
older	O
AML	B
patients	O
.	O

Prostaglandin	O
receptor	O
EP2	O
protects	O
dopaminergic	O
neurons	O
against	O
6	O
-	O
OHDA	O
-	O
mediated	O
low	O
oxidative	O
stress	O
.	O

Dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
selectively	O
die	O
in	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
,	O
but	O
it	O
is	O
unclear	O
how	O
and	O
why	O
this	O
occurs	O
.	O

Recent	O
findings	O
implicate	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
and	O
two	O
of	O
its	O
four	O
receptors	O
,	O
namely	O
EP1	O
and	O
EP2	O
,	O
as	O
mediators	O
of	O
degenerative	O
and	O
protective	O
events	O
in	O
situations	O
of	O
acute	O
and	O
chronic	B
neuronal	I
death	I
.	O

EP1	O
activation	O
can	O
exacerbate	O
excitotoxic	O
damage	O
in	O
stroke	B
models	O
and	O
our	O
recent	O
study	O
showed	O
that	O
EP1	O
activation	O
may	O
explain	O
the	O
selective	O
sensitivity	O
of	O
dopaminergic	O
neurons	O
to	O
oxidative	O
stress	O
.	O

Conversely	O
,	O
EP2	O
activation	O
may	O
be	O
neuroprotective	O
,	O
although	O
toxic	O
effects	O
have	O
also	O
been	O
demonstrated	O
.	O

Here	O
we	O
investigated	O
if	O
and	O
how	O
EP2	O
activation	O
might	O
alter	O
the	O
survival	O
of	O
dopaminergic	O
neurons	O
following	O
selective	O
low	O
-	O
level	O
oxidative	O
injury	O
evoked	O
by	O
the	O
neurotoxin	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
in	O
primary	O
neuronal	O
cultures	O
prepared	O
from	O
embryonic	O
rat	O
midbrain	O
.	O

We	O
found	O
that	O
cultured	O
dopaminergic	O
neurons	O
displayed	O
EP2	O
receptors	O
.	O

Butaprost	O
,	O
a	O
selective	O
EP2	O
agonist	O
,	O
significantly	O
reduced	O
6	O
-	O
OHDA	O
neurotoxicity	B
.	O

EP2	O
receptors	O
are	O
coupled	O
to	O
stimulatory	O
G	O
-	O
proteins	O
(	O
Gs	O
)	O
,	O
which	O
activate	O
adenylate	O
cyclase	O
,	O
increasing	O
cAMP	O
synthesis	O
,	O
which	O
then	O
activates	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
dibutyryl	O
cAMP	O
and	O
forskolin	O
reduced	O
dopaminergic	O
cell	O
loss	O
after	O
6	O
-	O
OHDA	O
exposure	O
.	O

Conversely	O
,	O
KT5720	O
and	O
H	O
-	O
89	O
,	O
two	O
structurally	O
distinct	O
high	O
-	O
affinity	O
PKA	O
inhibitors	O
,	O
abolished	O
the	O
protective	O
effect	O
of	O
butaprost	O
,	O
implicating	O
cAMP	O
-	O
dependent	O
PKA	O
activity	O
in	O
the	O
neuroprotection	O
by	O
EP2	O
activation	O
.	O

Finally	O
,	O
we	O
show	O
that	O
melanized	O
dopaminergic	O
neurons	O
in	O
the	O
human	O
SN	O
express	O
EP2	O
.	O

This	O
pathway	O
warrants	O
consideration	O
as	O
a	O
neuroprotective	O
strategy	O
for	O
PD	B
.	O

Utility	O
of	O
published	O
guidelines	O
on	O
the	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
in	O
the	O
elderly	O
.	O

Canadian	O
Consensus	O
guidelines	O
regarding	O
appropriate	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
recently	O
published	O
.	O

This	O
study	O
was	O
done	O
to	O
evaluate	O
the	O
application	O
of	O
these	O
guidelines	O
on	O
NSAID	O
practice	O
patterns	O
in	O
frail	O
elderly	O
patients	O
referred	O
to	O
a	O
specialist	O
Geriatric	O
Assessment	O
Clinic	O
.	O

A	O
retrospective	O
chart	O
review	O
was	O
undertaken	O
of	O
referrals	O
who	O
were	O
currently	O
prescribed	O
NSAIDs	O
.	O

Data	O
were	O
captured	O
on	O
age	O
,	O
sex	O
,	O
weight	O
,	O
diagnoses	O
,	O
medications	O
and	O
dosages	O
,	O
indication	O
for	O
NSAID	O
treatment	O
,	O
lying	O
BP	O
(	O
as	O
assessed	O
in	O
the	O
clinic	O
)	O
and	O
recent	O
serum	O
creatinine	O
result	O
.	O

Creatinine	O
clearance	O
was	O
subsequently	O
calculated	O
use	O
the	O
Cockcroft	O
-	O
Gault	O
equation	O
.	O

Complete	O
data	O
were	O
available	O
on	O
107	O
patients	O
(	O
68	O
%	O
women	O
,	O
average	O
age	O
80.6	O
years	O
)	O
.	O

Thirty	O
percent	O
were	O
on	O
a	O
traditional	O
NSAID	O
,	O
the	O
remainder	O
were	O
on	O
a	O
Coxib	O
.	O

Concomitant	O
aspirin	O
was	O
prescribed	O
in	O
37	O
%	O
.	O

Cytoprotection	O
was	O
being	O
used	O
in	O
38	O
%	O
and	O
did	O
not	O
increase	O
appreciably	O
in	O
patients	O
with	O
additional	O
risk	O
factors	O
for	O
GI	B
toxicity	I
,	O
i.e.	O
,	O
concomitant	O
aspirin	O
usage	O
(	O
35	O
%	O
)	O
,	O
and	O
history	O
of	O
GI	B
toxicity	I
(	O
48	O
%	O
)	O
.	O

Sixty	O
-	O
seven	O
were	O
taking	O
anti	O
-	O
hypertensive	O
medications	O
,	O
although	O
more	O
than	O
two	O
thirds	O
of	O
these	O
patients	O
were	O
uncontrolled	O
.	O

Newly	O
diagnosed	O
hypertension	B
was	O
present	O
in	O
19.6	O
%	O
.	O

Calculated	O
creatinine	O
clearance	O
revealed	O
moderate	O
to	O
severe	O
renal	B
impairment	I
in	O
79	O
%	O
of	O
subjects	O
,	O
although	O
serum	O
creatinine	O
was	O
only	O
elevated	O
in	O
18	O
%	O
.	O

In	O
total	O
,	O
70	O
%	O
of	O
subjects	O
were	O
found	O
to	O
have	O
relative	O
or	O
absolute	O
risk	O
factors	O
for	O
NSAID	O
therapy	O
.	O

Given	O
the	O
high	O
prevalence	O
of	O
potential	O
contraindications	O
to	O
anti	O
-	O
inflammatory	O
drug	O
usage	O
in	O
this	O
study	O
,	O
we	O
advocate	O
the	O
dissemination	O
and	O
application	O
of	O
these	O
guidelines	O
in	O
geriatric	O
patients	O
in	O
an	O
attempt	O
to	O
reduce	O
potential	O
morbidity	O
and	O
mortality	O
.	O

Practical	O
model	O
-	O
based	O
dose	O
finding	O
in	O
early	O
-	O
phase	O
clinical	O
trials	O
:	O
optimizing	O
tissue	O
plasminogen	O
activator	O
dose	O
for	O
treatment	O
of	O
ischemic	B
stroke	I
in	O
children	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
A	O
safe	O
and	O
effective	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
dose	O
for	O
childhood	O
stroke	B
has	O
not	O
been	O
established	O
.	O

This	O
article	O
describes	O
a	O
Bayesian	O
outcome	O
-	O
adaptive	O
method	O
for	O
determining	O
the	O
best	O
dose	O
of	O
an	O
experimental	O
agent	O
and	O
explains	O
how	O
this	O
method	O
was	O
used	O
to	O
design	O
a	O
dose	O
-	O
finding	O
trial	O
for	O
tPA	O
in	O
childhood	O
.	O

METHODS	O
:	O
The	O
method	O
assigns	O
doses	O
to	O
successive	O
cohorts	O
of	O
patients	O
on	O
the	O
basis	O
of	O
each	O
dose	O
's	O
desirability	O
,	O
quantified	O
in	O
terms	O
of	O
the	O
tradeoff	O
between	O
efficacy	O
and	O
toxicity	O
.	O

The	O
tradeoff	O
function	O
is	O
constructed	O
from	O
several	O
pairs	O
of	O
equally	O
desirable	O
(	O
efficacy	O
,	O
toxicity	O
)	O
probabilities	O
specified	O
by	O
the	O
physicians	O
planning	O
the	O
trial	O
.	O

Each	O
cohort	O
's	O
dose	O
is	O
chosen	O
adaptively	O
,	O
based	O
on	O
dose	O
-	O
outcome	O
data	O
from	O
the	O
patients	O
treated	O
previously	O
in	O
the	O
trial	O
,	O
to	O
optimize	O
the	O
efficacy	O
-	O
toxicity	O
tradeoff	O
.	O

Application	O
of	O
the	O
method	O
to	O
design	O
the	O
tPA	O
trial	O
is	O
described	O
,	O
including	O
a	O
computer	O
simulation	O
study	O
to	O
establish	O
design	O
properties	O
.	O

A	O
hypothetical	O
cohort	O
-	O
by	O
-	O
cohort	O
example	O
is	O
given	O
to	O
illustrate	O
how	O
the	O
method	O
works	O
during	O
trial	O
conduct	O
.	O

RESULTS	O
:	O
Because	O
only	O
a	O
dose	O
that	O
is	O
both	O
safe	O
and	O
efficacious	O
may	O
be	O
selected	O
and	O
the	O
method	O
combines	O
phase	O
I	O
and	O
phase	O
II	O
by	O
integrating	O
efficacy	O
and	O
toxicity	O
to	O
choose	O
doses	O
,	O
it	O
avoids	O
the	O
more	O
time	O
-	O
consuming	O
and	O
expensive	O
conventional	O
approach	O
of	O
conducting	O
a	O
phase	O
I	O
trial	O
based	O
on	O
toxicity	O
alone	O
followed	O
by	O
a	O
phase	O
II	O
trial	O
based	O
on	O
efficacy	O
alone	O
.	O

This	O
is	O
especially	O
useful	O
in	O
settings	O
with	O
low	O
accrual	O
rates	O
,	O
such	O
as	O
trials	O
of	O
tPA	O
for	O
pediatric	O
acute	B
ischemic	I
stroke	I
.	O

Pre	O
-	O
clinical	O
evidence	O
for	O
altered	O
absorption	O
and	O
biliary	O
excretion	O
of	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
in	O
combination	O
with	O
quercetin	O
:	O
possible	O
contribution	O
of	O
P	O
-	O
glycoprotein	O
.	O

P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
is	O
found	O
to	O
play	O
a	O
very	O
significant	O
role	O
in	O
intestinal	O
and	O
biliary	O
transport	O
of	O
irinotecan	O
and	O
its	O
active	O
metabolite	O
,	O
SN	O
-	O
38	O
.	O

This	O
makes	O
P	O
-	O
gp	O
inhibition	O
a	O
logical	O
strategy	O
for	O
improving	O
irinotecan	O
's	O
oral	O
efficacy	O
and	O
reducing	O
its	O
toxicity	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
the	O
most	O
suitable	O
P	O
-	O
gp	O
inhibitor	O
,	O
amongst	O
various	O
commonly	O
used	O
herbal	O
components	O
via	O
in	O
vitro	O
screening	O
;	O
followed	O
by	O
determination	O
of	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
various	O
components	O
(	O
quercetin	O
,	O
hesperitin	O
,	O
piperine	O
,	O
curcumin	O
and	O
naringenin	O
)	O
on	O
the	O
transport	O
of	O
irinotecan	O
.	O

The	O
secretory	O
transport	O
(	O
basolateral	O
-	O
to	O
-	O
apical	O
)	O
was	O
significantly	O
decreased	O
by	O
all	O
components	O
(	O
p	O
<	O
0.05	O
)	O
except	O
piperine	O
.	O

In	O
the	O
apical	O
-	O
to	O
-	O
basolateral	O
transport	O
,	O
quercetin	O
showed	O
the	O
highest	O
absorptive	O
permeability	O
enhancement	O
and	O
P	O
-	O
gp	O
interaction	O
potential	O
making	O
it	O
an	O
appropriate	O
candidate	O
for	O
further	O
in	O
vivo	O
studies	O
in	O
female	O
Wistar	O
rats	O
.	O

Quercetin	O
pre	O
-	O
treatment	O
resulted	O
in	O
increased	O
irinotecan	O
C	O
(	O
max	O
)	O
and	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
with	O
a	O
concomitant	O
decrease	O
in	O
t	O
(	O
max	O
)	O
,	O
plasma	O
clearance	O
and	O
volume	O
of	O
distribution	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
absolute	O
bioavailability	O
(	O
F	O
)	O
of	O
irinotecan	O
control	O
was	O
33	O
%	O
,	O
which	O
was	O
increased	O
to	O
43	O
%	O
(	O
1.3	O
fold	O
)	O
by	O
quercetin	O
administration	O
.	O

The	O
amounts	O
of	O
irinotecan	O
and	O
SN	O
-	O
38	O
eliminated	O
in	O
bile	O
in	O
control	O
rats	O
,	O
is	O
reduced	O
to	O
almost	O
half	O
when	O
treated	O
with	O
quercetin	O
.	O

Our	O
studies	O
not	O
only	O
propose	O
a	O
safe	O
approach	O
for	O
bioavailability	O
enhancement	O
and	O
reducing	O
toxicity	O
of	O
irinotecan	O
by	O
P	O
-	O
gp	O
inhibition	O
but	O
in	O
another	O
way	O
also	O
reiterate	O
the	O
significance	O
of	O
elucidating	O
herb	O
-	O
drug	O
interactions	O
for	O
future	O
insights	O
.	O

Fragrance	O
material	O
review	O
on	O
geraniol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
geraniol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

A	O
phase	O
II	O
trial	O
of	O
tetrathiomolybdate	O
after	O
surgery	O
for	O
malignant	B
mesothelioma	I
:	O
final	O
results	O
.	O

BACKGROUND	O
:	O
Tetrathiomolybdate	O
(	O
TM	O
)	O
is	O
an	O
oral	O
copper	O
-	O
depleting	O
agent	O
that	O
has	O
been	O
shown	O
to	O
inhibit	O
angiogenesis	O
,	O
and	O
angiogenesis	O
is	O
a	O
predictor	O
of	O
poor	O
prognosis	O
in	O
malignant	B
pleural	I
mesothelioma	I
.	O

We	O
hypothesized	O
that	O
cytoreduction	O
of	O
malignant	B
pleural	I
mesothelioma	I
followed	O
by	O
TM	O
will	O
delay	O
time	O
to	O
progression	O
.	O

METHODS	O
:	O
Between	O
November	O
2000	O
and	O
August	O
2003	O
,	O
30	O
patients	O
with	O
malignant	B
pleural	I
mesothelioma	I
received	O
postoperative	O
TM	O
beginning	O
4	O
to	O
6	O
weeks	O
after	O
surgery	O
at	O
a	O
dose	O
adjusted	O
to	O
keep	O
ceruloplasmin	O
between	O
5	O
and	O
15	O
mg	O
/	O
dL	O
)	O
.	O

Time	O
to	O
progression	O
was	O
compared	O
with	O
the	O
55	O
stage	O
I	O
and	O
II	O
patients	O
and	O
109	O
stage	O
III	O
patients	O
previously	O
treated	O
with	O
cytoreduction	O
by	O
one	O
of	O
us	O
(	O
H	O
.	O

P	O
.	O
)	O
.	O

RESULTS	O
:	O
The	O
30	O
patients	O
(	O
25	O
men	O
,	O
5	O
women	O
;	O
13	O
stage	O
I	O
and	O
II	O
,	O
17	O
stage	O
III	O
)	O
,	O
median	O
age	O
67	O
years	O
(	O
range	O
,	O
49	O
-	O
81	O
years	O
)	O
,	O
remained	O
on	O
TM	O
a	O
median	O
of	O
14.9	O
months	O
(	O
range	O
,	O
2	O
to	O
57	O
months	O
)	O
.	O

All	O
patients	O
reached	O
target	O
ceruloplasmin	O
levels	O
at	O
a	O
mean	O
of	O
34	O
+	O
/	O
-	O
2	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
30	O
to	O
39	O
days	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
levels	O
at	O
baseline	O
(	O
ceruloplasmin	O
=	O
45.2	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
)	O
decreased	O
from	O
2,086	O
+	O
/	O
-	O
390	O
pg	O
/	O
mL	O
to	O
1,250	O
+	O
/	O
-	O
712	O
pg	O
/	O
mL	O
(	O
p	O
<	O
0.002	O
)	O
at	O
target	O
ceruloplasmin	O
(	O
13	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
;	O
p	O
<	O
0.0001	O
from	O
baseline	O
)	O
.	O

The	O
time	O
to	O
progression	O
for	O
all	O
stage	O
I	O
or	O
II	O
TM	O
patients	O
was	O
20	O
months	O
whereas	O
that	O
of	O
55	O
stage	O
I	O
or	O
II	O
non	O
-	O
TM	O
-	O
treated	O
patients	O
was	O
10	O
months	O
(	O
p	O
=	O
0.046	O
versus	O
TM	O
)	O
.	O

No	O
differences	O
in	O
time	O
to	O
progression	O
for	O
the	O
stage	O
III	O
TM	O
patents	O
from	O
surgery	O
were	O
seen	O
(	O
7	O
months	O
)	O
.	O

CONCLUSIONS	O
:	O
Tetrathiomolybdate	O
has	O
antiangiogenic	O
effects	O
in	O
malignant	B
pleural	I
mesothelioma	I
patients	O
after	O
resection	O
of	O
gross	B
disease	I
,	O
and	O
exhibits	O
minimal	O
toxicity	O
and	O
comparable	O
efficacy	O
to	O
previous	O
multimodality	O
trials	O
.	O

Tetrathiomolybdate	O
should	O
be	O
evaluated	O
for	O
efficacy	O
in	O
combination	O
with	O
standard	O
malignant	B
pleural	I
mesothelioma	I
regimens	O
,	O
as	O
well	O
as	O
for	O
postsurgical	O
maintenance	O
therapy	O
.	O

Role	O
of	O
physical	O
chemical	O
properties	O
in	O
drug	O
relay	O
into	O
skin	O
compartments	O
.	O

The	O
ability	O
of	O
a	O
drug	O
to	O
reach	O
the	O
interstitial	O
fluid	O
is	O
an	O
important	O
aspect	O
of	O
drug	O
efficacy	O
-	O
as	O
a	O
possible	O
indicator	O
of	O
skin	O
and	O
cell	O
compartment	O
concentration	O
.	O

This	O
overview	O
addresses	O
the	O
relationship	O
of	O
the	O
physical	O
properties	O
of	O
several	O
antibiotics	O
to	O
their	O
ability	O
to	O
enter	O
the	O
interstitial	O
fluid	O
utilizing	O
a	O
cantharidin	O
blister	O
model	O
.	O

By	O
collecting	O
pharmacokinetic	O
data	O
for	O
12	O
antibiotics	O
administered	O
orally	O
and	O
11	O
intravenously	O
,	O
we	O
compared	O
the	O
fraction	O
of	O
drug	O
that	O
reaches	O
the	O
interstitial	O
fluid	O
(	O
AUC	O
(	O
blister	O
)	O
/	O
AUC	O
(	O
serum	O
)	O
)	O
to	O
partition	O
coefficients	O
.	O

Following	O
data	O
analysis	O
,	O
we	O
found	O
no	O
correlation	O
(	O
p	O
=	O
0.98	O
and	O
0.09	O
,	O
respectively	O
)	O
between	O
hydrophobicity	O
and	O
the	O
ability	O
to	O
reach	O
the	O
interstitium	O
.	O

Both	O
orally	O
and	O
intravenously	O
administered	O
antibiotics	O
display	O
a	O
strong	O
linear	O
correlation	O
(	O
p	O
<	O
0.001	O
and	O
p	O
=	O
0.006	O
,	O
respectively	O
)	O
in	O
the	O
total	O
concentration	O
found	O
in	O
the	O
serum	O
and	O
interstitial	O
fluid	O
indicating	O
that	O
serum	O
concentration	O
may	O
be	O
an	O
important	O
factor	O
in	O
dictating	O
interstitial	O
fluid	O
concentration	O
.	O

This	O
correlation	O
may	O
prove	O
useful	O
in	O
clinical	O
application	O
as	O
a	O
means	O
of	O
determining	O
interstitial	O
fluid	O
concentration	O
by	O
measuring	O
only	O
serum	O
levels	O
.	O

Systemic	O
therapy	O
for	O
unresectable	O
and	O
metastatic	B
transitional	I
cell	I
carcinoma	I
of	I
the	I
urothelium	I
:	O
first	O
-	O
line	O
and	O
beyond	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
The	O
review	O
aims	O
to	O
provide	O
an	O
overview	O
of	O
recent	O
advances	O
and	O
future	O
research	O
direction	O
in	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

RECENT	O
FINDINGS	O
:	O
Early	O
data	O
of	O
the	O
randomized	O
phase	O
III	O
study	O
comparing	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
with	O
gemcitabine	O
plus	O
cisplatin	O
for	O
advanced	O
urothelial	B
cancer	I
detected	O
no	O
survival	O
difference	O
.	O

A	O
phase	O
II	O
study	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
trastuzumab	O
,	O
carboplatin	O
,	O
gemcitabine	O
,	O
and	O
paclitaxel	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
-	O
2	O
/	O
neu	O
-	O
positive	O
advanced	O
urothelial	B
carcinoma	I
and	O
reported	O
promising	O
results	O
.	O

Renal	O
-	O
sparing	O
regimens	O
are	O
under	O
active	O
development	O
.	O

A	O
nonrandomized	O
comparison	O
of	O
the	O
3	O
-	O
week	O
with	O
the	O
4	O
-	O
week	O
schedule	O
for	O
gemcitabine	O
and	O
cisplatin	O
showed	O
that	O
the	O
3	O
-	O
week	O
schedule	O
had	O
less	O
hematological	B
toxicity	I
and	O
better	O
dose	O
intensity	O
.	O

Potential	O
molecular	O
markers	O
such	O
as	O
excision	O
repair	O
cross	O
-	O
complementation	O
group	O
1	O
,	O
emmprin	O
,	O
and	O
survivin	O
for	O
survival	O
and	O
/	O
or	O
platinum	O
resistance	O
in	O
patients	O
with	O
transitional	B
cell	I
carcinoma	I
showed	O
promise	O
.	O

SUMMARY	O
:	O
Recent	O
data	O
do	O
not	O
support	O
change	O
in	O
the	O
current	O
standard	O
of	O
care	O
for	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

Clinical	O
testing	O
of	O
emerging	O
anticancer	O
therapies	O
using	O
new	O
agents	O
,	O
new	O
combinations	O
,	O
and	O
new	O
approaches	O
is	O
under	O
active	O
investigation	O
.	O

Rational	O
combination	O
and	O
new	O
strategy	O
in	O
clinical	O
trial	O
design	O
are	O
critical	O
for	O
new	O
drug	O
development	O
for	O
transitional	B
cell	I
carcinoma	I
.	O

Catalase	O
ameliorates	O
polychlorinated	O
biphenyl	O
-	O
induced	O
cytotoxicity	B
in	O
nonmalignant	O
human	O
breast	O
epithelial	O
cells	O
.	O

Polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
are	O
environmental	O
chemical	O
contaminants	O
believed	O
to	O
adversely	O
affect	O
cellular	O
processes	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
PCB	O
-	O
induced	O
changes	O
in	O
the	O
levels	O
of	O
cellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induce	O
DNA	O
damage	O
resulting	O
in	O
cytotoxicity	B
.	O

Exponentially	O
growing	O
cultures	O
of	O
human	O
nonmalignant	O
breast	O
epithelial	O
cells	O
(	O
MCF10A	O
)	O
were	O
incubated	O
with	O
PCBs	O
for	O
3	O
days	O
and	O
assayed	O
for	O
cell	O
number	O
,	O
ROS	O
levels	O
,	O
DNA	O
damage	O
,	O
and	O
cytotoxicity	B
.	O

Exposure	O
to	O
2,2	O
'	O
,	O
4,4	O
'	O
,	O
5,5	O
'	O
-	O
hexachlorobiphenyl	O
(	O
PCB153	O
)	O
or	O
2	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
benzo	O
-	O
1,4	O
-	O
quinone	O
(	O
4	O
-	O
Cl	O
-	O
BQ	O
)	O
,	O
a	O
metabolite	O
of	O
4	O
-	O
chlorobiphenyl	O
(	O
PCB3	O
)	O
,	O
significantly	O
decreased	O
cell	O
number	O
and	O
MTS	O
reduction	O
and	O
increased	O
the	O
percentage	O
of	O
cells	O
with	O
sub	O
-	O
G1	O
DNA	O
content	O
.	O

Results	O
from	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
showed	O
a	O
4	O
-	O
fold	O
increase	O
in	O
the	O
steady	O
-	O
state	O
levels	O
of	O
ROS	O
,	O
which	O
was	O
suppressed	O
in	O
cells	O
pretreated	O
with	O
catalase	O
.	O

EPR	O
measurements	O
in	O
cells	O
treated	O
with	O
4	O
-	O
Cl	O
-	O
BQ	O
detected	O
the	O
presence	O
of	O
a	O
semiquinone	O
radical	O
,	O
suggesting	O
that	O
the	O
increased	O
levels	O
of	O
ROS	O
could	O
be	O
due	O
to	O
the	O
redox	O
cycling	O
of	O
4	O
-	O
Cl	O
-	O
BQ	O
.	O

A	O
dose	O
-	O
dependent	O
increase	O
in	O
micronuclei	O
frequency	O
was	O
observed	O
in	O
PCB	O
-	O
treated	O
cells	O
,	O
consistent	O
with	O
an	O
increase	O
in	O
histone	O
2AX	O
phosphorylation	O
.	O

Treatment	O
of	O
cells	O
with	O
catalase	O
blunted	O
the	O
PCB	O
-	O
induced	O
increase	O
in	O
micronuclei	O
frequency	O
and	O
H2AX	O
phosphorylation	O
that	O
was	O
consistent	O
with	O
an	O
increase	O
in	O
cell	O
survival	O
.	O

Our	O
results	O
demonstrate	O
a	O
PCB	O
-	O
induced	O
increase	O
in	O
cellular	O
levels	O
of	O
ROS	O
causing	O
DNA	O
damage	O
,	O
resulting	O
in	O
cell	O
killing	O
.	O

Inhibition	O
of	O
class	O
I	O
histone	O
deacetylase	O
with	O
an	O
apicidin	O
derivative	O
prevents	O
cardiac	B
hypertrophy	I
and	O
failure	O
.	O

AIMS	O
:	O
Recent	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
chromatin	O
remodelling	O
via	O
histone	O
acetylation	O
/	O
deacetylation	O
for	O
the	O
control	O
of	O
cardiac	O
gene	O
expression	O
.	O

Specific	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
can	O
,	O
in	O
fact	O
,	O
play	O
a	O
positive	O
or	O
negative	O
role	O
in	O
determining	O
cardiac	O
myocyte	O
(	O
CM	O
)	O
size	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
effect	O
on	O
hypertrophy	B
development	O
of	O
three	O
inhibitors	O
(	O
HDACi	O
)	O
of	O
class	O
I	O
HDACs	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
compounds	O
were	O
first	O
analysed	O
in	O
vitro	O
by	O
scoring	O
hypertrophy	B
,	O
expression	O
of	O
foetal	O
genes	O
,	O
and	O
apoptosis	O
of	O
neonatal	O
rat	O
CMs	O
stimulated	O
with	O
phenylephrine	O
,	O
an	O
alpha1	O
-	O
adrenergic	O
agonist	O
.	O

This	O
initial	O
screening	O
indicated	O
that	O
a	O
truncated	O
derivative	O
of	O
apicidin	O
with	O
class	O
I	O
HDAC	O
specificity	O
,	O
denoted	O
API	O
-	O
D	O
,	O
had	O
the	O
highest	O
efficacy	O
to	O
toxicity	O
ratio	O
,	O
and	O
was	O
thus	O
selected	O
for	O
further	O
analysis	O
in	O
vivo	O
.	O

Administration	O
of	O
this	O
drug	O
significantly	O
decreased	O
myocardial	B
hypertrophy	I
and	O
foetal	O
gene	O
expression	O
after	O
1	O
week	O
of	O
pressure	O
overload	O
induced	O
by	O
thoracic	O
aortic	O
constriction	O
(	O
TAC	O
)	O
in	O
mice	O
.	O

After	O
9	O
weeks	O
of	O
TAC	O
,	O
when	O
manifest	O
heart	B
failure	I
is	O
encountered	O
,	O
mice	O
treated	O
with	O
API	O
-	O
D	O
presented	O
with	O
significantly	O
improved	O
echocardiographic	O
and	O
haemodynamic	O
parameters	O
of	O
cardiac	O
function	O
when	O
compared	O
with	O
untreated	O
TAC	O
-	O
operated	O
mice	O
.	O

CONCLUSION	O
:	O
The	O
apicidin	O
derivative	O
,	O
API	O
-	O
D	O
,	O
is	O
capable	O
of	O
reducing	O
hypertrophy	B
and	O
,	O
consequently	O
,	O
the	O
transition	O
to	O
heart	B
failure	I
in	O
mice	O
subjected	O
to	O
TAC	O
.	O

Treatment	O
with	O
this	O
substance	O
,	O
therefore	O
,	O
holds	O
promise	O
as	O
an	O
important	O
therapeutic	O
option	O
for	O
heart	B
failure	I
.	O

Application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
metabolism	O
and	O
in	O
metabolism	B
-	I
mediated	I
toxicity	I
studies	O
.	O

Stable	O
isotope	O
-	O
labeled	O
compounds	O
have	O
been	O
synthesized	O
and	O
utilized	O
by	O
scientists	O
from	O
various	O
areas	O
of	O
biomedical	O
research	O
during	O
the	O
last	O
several	O
decades	O
.	O

Compounds	O
labeled	O
with	O
stable	O
isotopes	O
,	O
such	O
as	O
deuterium	O
and	O
carbon	O
-	O
13	O
,	O
have	O
been	O
used	O
effectively	O
by	O
drug	O
metabolism	O
scientists	O
and	O
toxicologists	O
to	O
gain	O
better	O
understanding	O
of	O
drugs	O
'	O
disposition	O
and	O
their	O
potential	O
role	O
in	O
target	B
organ	I
toxicities	I
.	O

The	O
combination	O
of	O
stable	O
isotope	O
-	O
labeling	O
techniques	O
with	O
mass	O
spectrometry	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
,	O
which	O
allows	O
rapid	O
acquisition	O
and	O
interpretation	O
of	O
data	O
,	O
has	O
promoted	O
greater	O
use	O
of	O
these	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
(	O
ADME	O
)	O
studies	O
.	O

Examples	O
of	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
elucidating	O
structures	O
of	O
metabolites	O
and	O
delineating	O
complex	O
metabolic	O
pathways	O
are	O
presented	O
in	O
this	O
review	O
.	O

The	O
application	O
of	O
labeled	O
compounds	O
in	O
mechanistic	O
toxicity	O
studies	O
will	O
be	O
discussed	O
by	O
providing	O
an	O
example	O
of	O
how	O
strategic	O
placement	O
of	O
a	O
deuterium	O
atom	O
in	O
a	O
drug	O
molecule	O
mitigated	O
specific	O
-	O
specific	O
renal	B
toxicity	I
.	O

Other	O
examples	O
from	O
the	O
literature	O
demonstrating	O
the	O
application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
understanding	O
metabolism	B
-	I
mediated	I
toxicities	I
are	O
presented	O
.	O

Furthermore	O
,	O
an	O
example	O
of	O
how	O
a	O
stable	O
isotope	O
-	O
labeled	O
compound	O
was	O
utilized	O
to	O
better	O
understand	O
some	O
of	O
the	O
gene	O
changes	O
in	O
toxicogenomic	O
studies	O
is	O
discussed	O
.	O

The	O
interpretation	O
of	O
large	O
sets	O
of	O
data	O
produced	O
from	O
toxicogenomics	O
studies	O
can	O
be	O
a	O
challenge	O
.	O

One	O
approach	O
that	O
could	O
be	O
used	O
to	O
simplify	O
interpretation	O
of	O
the	O
data	O
,	O
especially	O
from	O
studies	O
designed	O
to	O
link	O
gene	O
changes	O
with	O
the	O
formation	O
of	O
reactive	O
metabolites	O
thought	O
to	O
be	O
responsible	O
for	O
toxicities	O
,	O
is	O
through	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
.	O

This	O
is	O
a	O
relatively	O
unexplored	O
territory	O
and	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

The	O
employment	O
of	O
analytical	O
techniques	O
,	O
especially	O
mass	O
spectrometry	O
and	O
NMR	O
,	O
used	O
in	O
conjunction	O
with	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
to	O
establish	O
and	O
understand	O
mechanistic	O
link	O
between	O
reactive	O
metabolite	O
formation	O
,	O
genomic	O
,	O
and	O
proteomic	O
changes	O
and	O
onset	O
of	O
toxicity	O
is	O
proposed	O
.	O

The	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
early	O
human	O
ADME	O
studies	O
as	O
a	O
way	O
of	O
identifying	O
and	O
possibly	O
quantifying	O
all	O
drug	O
-	O
related	O
components	O
present	O
in	O
systemic	O
circulation	O
is	O
suggested	O
.	O

Delayed	O
initiation	O
of	O
breast	O
development	O
in	O
girls	O
with	O
higher	O
prenatal	O
dioxin	O
exposure	O
;	O
a	O
longitudinal	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
While	O
many	O
studies	O
have	O
assessed	O
the	O
health	O
impacts	O
of	O
PCDD	O
/	O
Fs	O
and	O
PCBs	O
on	O
animals	O
and	O
humans	O
,	O
long	O
-	O
term	O
consequences	O
for	O
especially	O
adolescents	O
,	O
have	O
not	O
(	O
yet	O
)	O
been	O
well	O
documented	O
.	O

This	O
is	O
certainly	O
also	O
true	O
for	O
the	O
effects	O
of	O
PBDE	O
exposure	O
.	O

As	O
part	O
of	O
a	O
longitudinal	O
cohort	O
study	O
,	O
now	O
well	O
into	O
its	O
second	O
decade	O
,	O
effects	O
of	O
perinatal	O
and	O
current	O
PCDD	O
/	O
F	O
exposure	O
,	O
as	O
well	O
as	O
current	O
dl	O
-	O
PCB	O
and	O
PBDE	O
exposures	O
,	O
on	O
puberty	O
,	O
were	O
assessed	O
.	O

STUDY	O
DESIGN	O
:	O
Prenatal	O
,	O
lactational	O
and	O
current	O
PCDD	O
/	O
F	O
,	O
dl	O
-	O
PCB	O
and	O
PBDE	O
concentrations	O
were	O
determined	O
using	O
GC	O
-	O
MS	O
.	O

Pubertal	O
development	O
and	O
growth	O
were	O
assessed	O
by	O
means	O
of	O
physical	O
examination	O
and	O
the	O
Tanner	O
scale	O
.	O

33	O
Children	O
(	O
born	O
between	O
1986	O
and	O
1991	O
)	O
consented	O
to	O
the	O
current	O
follow	O
-	O
up	O
study	O
.	O

Outcomes	O
were	O
evaluated	O
using	O
linear	O
regression	O
or	O
the	O
non	O
parametric	O
Spearman	O
's	O
correlation	O
coefficient	O
.	O

RESULTS	O
:	O
A	O
delay	O
in	O
initiation	O
of	O
breast	O
development	O
was	O
found	O
in	O
girls	O
(	O
n	O
=	O
18	O
)	O
with	O
higher	O
prenatal	O
(	O
p	O
=	O
0.023	O
)	O
and	O
lactational	O
PCDD	O
/	O
F	O
exposure	O
(	O
p	O
=	O
0.048	O
)	O
.	O

The	O
males	O
revealed	O
a	O
negative	O
trend	O
with	O
age	O
at	O
first	O
ejaculation	O
.	O

For	O
other	O
endpoints	O
on	O
puberty	O
and	O
growth	O
(	O
pubic	O
hair	O
,	O
axillary	O
hair	O
,	O
genital	O
stage	O
,	O
length	O
,	O
BMI	O
,	O
testicular	O
volume	O
,	O
menarche	O
)	O
no	O
significant	O
relation	O
was	O
found	O
with	O
any	O
of	O
the	O
measured	O
compounds	O
.	O

DISCUSSION	O
AND	O
CONCLUSION	O
:	O
A	O
relation	O
between	O
prenatal	O
PCDD	O
/	O
F	O
exposure	O
and	O
later	O
initiation	O
of	O
breast	O
development	O
was	O
seen	O
.	O

A	O
Belgian	O
study	O
found	O
a	O
delay	O
in	O
breast	O
development	O
with	O
higher	O
current	O
serum	O
concentrations	O
of	O
dioxin	O
-	O
like	O
compounds	O
.	O

The	O
initiation	O
of	O
puberty	O
is	O
a	O
complex	O
process	O
and	O
it	O
is	O
yet	O
not	O
clear	O
how	O
dioxin	O
-	O
like	O
compounds	O
precisely	O
affect	O
this	O
process	O
prenatally	O
.	O

Further	O
follow	O
-	O
up	O
into	O
adulthood	O
is	O
warranted	O
,	O
in	O
order	O
to	O
detect	O
the	O
possibility	O
of	O
developing	O
malignancies	B
and	O
fertility	O
problems	O
.	O

Preparation	O
of	O
BMP	O
-	O
2	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
stabilized	O
by	O
polymer	O
coating	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
preparation	O
process	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
(	O
BMP	O
-	O
2	O
)	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
,	O
and	O
to	O
assess	O
the	O
bioactivity	O
of	O
BMP	O
-	O
2	O
encapsulated	O
in	O
such	O
NPs	O
.	O

METHODS	O
:	O
The	O
NPs	O
were	O
prepared	O
by	O
a	O
coacervation	O
method	O
,	O
and	O
the	O
effects	O
of	O
process	O
parameters	O
on	O
NP	O
size	O
and	O
polydispersity	O
were	O
examined	O
.	O

Polymer	O
coated	O
NPs	O
were	O
characterized	O
with	O
respect	O
to	O
amount	O
of	O
adsorbed	O
polymer	O
,	O
particle	O
size	O
and	O
zeta	O
potential	O
.	O

Using	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
,	O
biocompatibility	O
of	O
the	O
NPs	O
was	O
investigated	O
by	O
the	O
3	O
-	O
(	O
4,5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2,5	O
-	O
diphenyl	O
-	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
Assay	O
,	O
and	O
bioactivity	O
of	O
the	O
encapsulated	O
BMP	O
-	O
2	O
was	O
investigated	O
by	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
induction	O
and	O
calcification	O
.	O

RESULTS	O
:	O
The	O
size	O
of	O
NPs	O
could	O
be	O
controlled	O
in	O
the	O
50	O
-	O
400	O
nm	O
range	O
by	O
process	O
parameters	O
including	O
BSA	O
concentration	O
,	O
non	O
-	O
solvent	O
:	O
solvent	O
ratio	O
and	O
pH	O
value	O
.	O

After	O
coating	O
with	O
cationic	O
polymers	O
,	O
the	O
particle	O
size	O
and	O
zeta	O
potential	O
were	O
significantly	O
increased	O
.	O

MTT	O
assay	O
indicated	O
no	O
toxicity	O
of	O
both	O
the	O
uncoated	O
and	O
coated	O
NPs	O
on	O
BMSC	O
.	O

Based	O
on	O
ALP	O
induction	O
and	O
calcification	O
,	O
full	O
retention	O
of	O
BMP	O
-	O
2	O
bioactivity	O
was	O
retained	O
in	O
the	O
polymer	O
-	O
coated	O
NPs	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
described	O
a	O
preparation	O
procedure	O
for	O
BSA	O
NPs	O
with	O
controllable	O
particle	O
size	O
,	O
and	O
such	O
polymer	O
-	O
coated	O
BSA	O
NPs	O
are	O
promising	O
delivery	O
agents	O
for	O
local	O
and	O
systemic	O
administration	O
of	O
BMP	O
-	O
2	O
in	O
bone	O
regeneration	O
.	O

Effect	O
of	O
cement	O
dust	O
exposure	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
in	O
cement	O
mill	O
workers	O
.	O

OBJECTIVES	O
:	O
Exposure	O
to	O
cement	O
dust	O
can	O
cause	O
various	O
occupational	O
health	O
problems	O
due	O
to	O
its	O
increasing	O
incidence	O
and	O
long	O
-	O
term	O
complications	O
.	O

However	O
,	O
the	O
influence	O
of	O
cement	O
dust	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
,	O
has	O
not	O
as	O
yet	O
been	O
investigated	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
study	O
was	O
to	O
measure	O
the	O
phagocytic	O
activity	O
of	O
PMNs	O
by	O
assessing	O
chemilumiscence	O
(	O
CL	O
)	O
response	O
in	O
cement	O
mill	O
workers	O
and	O
controls	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
50	O
volunteer	O
males	O
,	O
aged	O
25	O
-	O
60	O
years	O
,	O
apparently	O
healthy	O
and	O
nonsmoking	O
,	O
were	O
randomly	O
selected	O
from	O
among	O
cement	O
mill	O
workers	O
.	O

These	O
workers	O
were	O
further	O
classified	O
into	O
subgroups	O
based	O
on	O
exposure	O
duration	O
of	O
less	O
than	O
10	O
,	O
10	O
-	O
20	O
,	O
and	O
more	O
than	O
20	O
years	O
.	O

The	O
controls	O
were	O
50	O
healthy	O
,	O
nonsmoking	O
,	O
males	O
who	O
matched	O
the	O
study	O
group	O
with	O
respect	O
to	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
socioeconomic	O
status	O
.	O

The	O
phagocytic	O
function	O
of	O
PMNs	O
,	O
stimulated	O
with	O
opsonized	O
zymosan	O
,	O
was	O
determined	O
by	O
measuring	O
CL	O
response	O
.	O

RESULTS	O
:	O
The	O
findings	O
show	O
a	O
significant	O
decrease	O
in	O
phagocytic	O
activity	O
of	O
PMNs	O
[	O
PMNs	O
OPZ	O
p	O
<	O
0.005	O
]	O
in	O
cement	O
mill	O
workers	O
compared	O
to	O
controls	O
.	O

CONCLUSION	O
:	O
It	O
is	O
concluded	O
that	O
exposure	O
to	O
cement	O
dust	O
can	O
impair	O
the	O
phagocytic	O
function	O
of	O
PMNs	O
which	O
is	O
reflected	O
in	O
decreased	O
chemiluminescence	O
response	O
.	O

Tadalafil	O
administered	O
once	O
daily	O
for	O
lower	O
urinary	B
tract	I
symptoms	I
secondary	O
to	O
benign	B
prostatic	I
hyperplasia	I
:	O
a	O
dose	O
finding	O
study	O
.	O

PURPOSE	O
:	O
Phosphodiesterase	O
type	O
5	O
inhibitors	O
are	O
widely	O
used	O
to	O
treat	O
erectile	B
dysfunction	I
.	O

Preliminary	O
data	O
have	O
suggested	O
phosphodiesterase	O
type	O
5	O
inhibitor	O
efficacy	O
in	O
men	O
with	O
lower	O
urinary	B
tract	I
symptoms	I
associated	O
with	O
clinical	O
benign	B
prostatic	I
hyperplasia	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
a	O
4	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
1,058	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
were	O
randomly	O
allocated	O
to	O
receive	O
12	O
-	O
week	O
,	O
once	O
daily	O
treatment	O
with	O
placebo	O
or	O
tadalafil	O
(	O
2.5	O
,	O
5	O
,	O
10	O
or	O
20	O
mg	O
)	O
.	O

RESULTS	O
:	O
The	O
International	O
Prostate	O
Symptom	O
Score	O
least	O
squares	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
point	O
was	O
significantly	O
improved	O
for	O
2.5	O
(	O
-	O
3.9	O
,	O
p	O
=	O
0.015	O
)	O
,	O
5	O
(	O
-	O
4.9	O
,	O
p	O
<	O
0.001	O
)	O
,	O
10	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
and	O
20	O
mg	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
tadalafil	O
compared	O
to	O
placebo	O
(	O
-	O
2.3	O
)	O
.	O

International	O
Prostate	O
Symptom	O
Score	O
improvements	O
at	O
4	O
,	O
8	O
and	O
12	O
weeks	O
were	O
significant	O
for	O
all	O
tadalafil	O
doses	O
and	O
they	O
demonstrated	O
a	O
dose	O
-	O
response	O
relationship	O
.	O

Tadalafil	O
(	O
2.5	O
mg	O
)	O
significantly	O
improved	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
obstructive	O
subscore	O
and	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
,	O
the	O
latter	O
in	O
sexually	O
active	O
men	O
with	O
a	O
history	O
of	O
erectile	B
dysfunction	I
.	O

Statistically	O
significant	O
improvements	O
were	O
noted	O
for	O
5	O
,	O
10	O
and	O
20	O
mg	O
tadalafil	O
compared	O
to	O
placebo	O
,	O
as	O
assessed	O
by	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
irritative	O
and	O
obstructive	O
subscores	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
Quality	O
of	O
Life	O
,	O
Benign	B
Prostatic	I
Hyperplasia	I
Impact	O
Index	O
(	O
nonsignificant	O
for	O
10	O
mg	O
)	O
,	O
Global	O
Assessment	O
Question	O
and	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
.	O

No	O
statistically	O
significant	O
effect	O
of	O
treatment	O
compared	O
to	O
placebo	O
was	O
noted	O
for	O
peak	O
flow	O
at	O
any	O
tadalafil	O
dose	O
.	O

Treatment	O
emergent	O
adverse	O
events	O
were	O
infrequent	O
in	O
all	O
tadalafil	O
groups	O
.	O

CONCLUSIONS	O
:	O
Once	O
daily	O
tadalafil	O
demonstrated	O
clinically	O
meaningful	O
and	O
statistically	O
significant	O
efficacy	O
and	O
it	O
was	O
well	O
tolerated	O
in	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
.	O

Of	O
the	O
doses	O
studied	O
5	O
mg	O
tadalafil	O
appeared	O
to	O
provide	O
a	O
positive	O
risk	O
-	O
benefit	O
profile	O
.	O

Mitochondrial	O
dysfunction	O
and	O
delayed	O
hepatotoxicity	B
:	O
another	O
lesson	O
from	O
troglitazone	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Troglitazone	O
was	O
approved	O
for	O
treatment	O
of	O
type	B
2	I
diabetes	I
mellitus	I
,	O
but	O
by	O
2000	O
it	O
had	O
been	O
removed	O
from	O
all	O
world	O
markets	O
due	O
to	O
severe	O
drug	O
-	O
induced	O
liver	B
injury	I
.	O

Even	O
today	O
,	O
we	O
still	O
do	O
not	O
know	O
how	O
many	O
patients	O
sustained	O
a	O
long	O
-	O
term	O
liver	B
injury	I
.	O

No	O
system	O
is	O
in	O
place	O
to	O
acquire	O
that	O
knowledge	O
.	O

Regarding	O
toxicity	O
mechanisms	O
,	O
controversy	O
persists	O
as	O
to	O
which	O
ones	O
are	O
class	O
effects	O
of	O
thiazolidinediones	O
(	O
TZDs	O
)	O
and	O
which	O
are	O
unique	O
to	O
troglitazone	O
.	O

This	O
study	O
aims	O
to	O
provide	O
long	O
-	O
term	O
outcome	O
data	O
and	O
new	O
insights	O
on	O
mechanisms	O
of	O
troglitazone	O
-	O
induced	O
liver	B
injury	I
.	O

METHODS	O
:	O
This	O
case	O
series	O
reports	O
the	O
liver	O
injuries	O
sustained	O
by	O
eleven	O
type	O
2	O
diabetic	O
patients	O
treated	O
with	O
troglitazone	O
between	O
1997	O
and	O
2000	O
.	O

Exhaustive	O
review	O
of	O
medical	O
records	O
was	O
performed	O
for	O
all	O
patients	O
.	O

Long	O
-	O
term	O
outcomes	O
were	O
available	O
for	O
all	O
the	O
non	O
-	O
fatal	O
cases	O
.	O

A	O
comprehensive	O
literature	O
review	O
was	O
also	O
performed	O
.	O

RESULTS	O
:	O
Long	O
-	O
term	O
liver	B
injury	I
progressing	O
to	O
cirrhosis	B
was	O
identified	O
in	O
seven	O
patients	O
.	O

All	O
eleven	O
cases	O
had	O
liver	B
injury	I
patterns	O
consistent	O
with	O
troglitazone	O
toxicity	O
.	O

Analysis	O
of	O
these	O
cases	O
and	O
of	O
the	O
experimental	O
troglitazone	O
toxicity	O
data	O
points	O
to	O
mitochondrial	B
toxicity	I
as	O
a	O
central	O
factor	O
.	O

The	O
general	O
clinical	O
patterns	O
of	O
mitochondrial	B
hepatotoxic	I
events	I
are	O
reviewed	O
,	O
as	O
are	O
the	O
implications	O
for	O
other	O
members	O
of	O
the	O
TZD	O
family	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
This	O
analysis	O
enables	O
the	O
liver	B
injury	I
induced	O
by	O
troglitazone	O
to	O
be	O
better	O
understood	O
.	O

In	O
future	O
cases	O
of	O
delayed	O
drug	O
-	O
induced	O
liver	B
injury	I
that	O
progresses	O
after	O
discontinuation	O
,	O
the	O
possibility	O
of	O
mitochondrial	B
toxicity	I
should	O
be	O
considered	O
.	O

When	O
appropriate	O
,	O
this	O
can	O
then	O
be	O
evaluated	O
experimentally	O
.	O

Such	O
proactive	O
investigation	O
may	O
anticipate	O
clinical	O
risk	O
before	O
a	O
large	O
-	O
scale	O
therapeutic	O
misadventure	O
occurs	O
.	O

Drug	O
-	O
induced	O
liver	B
injury	I
due	O
to	O
mitochondrial	O
hepatotoxins	O
may	O
be	O
less	O
unpredictable	O
than	O
has	O
previously	O
been	O
surmised	O
.	O

Understanding	O
the	O
genetic	O
causes	O
of	O
inter	O
-	O
patient	O
variability	O
.	O

Clinical	O
relevance	O
with	O
focus	O
on	O
cardiovascular	O
drugs	O
.	O

There	O
is	O
a	O
large	O
inter	O
-	O
patient	O
variability	O
concerning	O
the	O
response	O
to	O
drug	O
therapy	O
and	O
a	O
great	O
interest	O
for	O
determining	O
the	O
causes	O
of	O
this	O
variability	O
.	O

This	O
review	O
takes	O
into	O
discussion	O
some	O
aspects	O
of	O
cardiovascular	O
drugs	O
metabolism	O
and	O
transport	O
,	O
pointing	O
out	O
the	O
effects	O
of	O
genetic	O
variation	O
.	O

Isoenyzmes	O
belonging	O
to	O
the	O
Cytochrome	O
P450	O
super	O
family	O
have	O
an	O
important	O
role	O
in	O
cardiovascular	O
drug	O
metabolism	O
,	O
namely	O
CYP	O
1A2	O
;	O
CYP	O
3A	O
;	O
CYP	O
2C19	O
;	O
CYP2C9	O
;	O
CYP	O
2D6	O
,	O
involved	O
in	O
the	O
oxidative	O
phase	O
and	O
also	O
N	O
-	O
acetyltransferase	O
2	O
,	O
involved	O
in	O
the	O
conjungative	O
phase	O
of	O
the	O
metabolism	O
.	O

P	O
-	O
glycoprotein	O
is	O
implied	O
in	O
cardiovascular	O
drug	O
transport	O
.	O

Polymorphisms	O
of	O
those	O
enzymes	O
and	O
transport	O
protein	O
result	O
in	O
different	O
phenotypes	O
,	O
that	O
is	O
the	O
case	O
of	O
CYP	O
isoenyzmes	O
with	O
abolished	O
,	O
low	O
or	O
increased	O
activity	O
and	O
in	O
the	O
case	O
of	O
N	O
-	O
acetyltransferase	O
2	O
,	O
slow	O
,	O
intermediate	O
and	O
rapid	O
acetylator	O
phenotypes	O
.	O

There	O
is	O
hope	O
that	O
,	O
in	O
the	O
future	O
,	O
a	O
more	O
individualized	O
treatment	O
of	O
a	O
certain	O
disease	O
,	O
with	O
minimum	O
adverse	O
effects	O
and	O
a	O
maximum	O
therapeutic	O
effect	O
,	O
will	O
be	O
available	O
,	O
by	O
means	O
of	O
genetic	O
testing	O
.	O

The	O
islet	O
beta	O
-	O
cell	O
:	O
fuel	O
responsive	O
and	O
vulnerable	O
.	O

The	O
pancreatic	O
beta	O
-	O
cell	O
senses	O
blood	O
nutrient	O
levels	O
and	O
is	O
modulated	O
by	O
neurohormonal	O
signals	O
so	O
that	O
it	O
secretes	O
insulin	O
according	O
to	O
the	O
need	O
of	O
the	O
organism	O
.	O

Nutrient	O
sensing	O
involves	O
marked	O
metabolic	O
activation	O
,	O
resulting	O
in	O
the	O
production	O
of	O
coupling	O
signals	O
that	O
promote	O
insulin	O
biosynthesis	O
and	O
secretion	O
.	O

The	O
beta	O
-	O
cell	O
's	O
high	O
capacity	O
for	O
nutrient	O
sensing	O
,	O
however	O
,	O
necessitates	O
reduced	O
protection	O
to	O
nutrient	B
toxicity	I
.	O

This	O
potentially	O
explains	O
why	O
in	O
susceptible	O
individuals	O
,	O
chronic	O
fuel	O
surfeit	O
results	O
in	O
beta	O
-	O
cell	O
failure	O
and	O
type	B
2	I
diabetes	I
.	O

Here	O
we	O
discuss	O
recent	O
insights	O
into	O
first	O
,	O
the	O
biochemical	O
basis	O
of	O
beta	O
-	O
cell	O
signaling	O
in	O
response	O
to	O
glucose	O
,	O
amino	O
acids	O
and	O
fatty	O
acids	O
,	O
and	O
second	O
,	O
beta	O
-	O
cell	O
nutrient	O
detoxification	O
.	O

We	O
emphasize	O
the	O
emerging	O
role	O
of	O
glycerolipid	O
/	O
fatty	O
acid	O
cycling	O
in	O
these	O
processes	O
.	O

Recurrent	O
seizures	B
in	O
patients	O
with	O
dementia	B
:	O
frequency	O
,	O
seizure	B
types	O
,	O
and	O
treatment	O
outcome	O
.	O

OBJECTIVE	O
:	O
Patients	O
with	O
a	O
primary	O
neurodegenerative	B
disorder	I
associated	O
with	O
cognitive	B
impairment	I
are	O
at	O
increased	O
risk	O
for	O
epilepsy	B
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
seizure	B
type	O
(	O
s	O
)	O
,	O
etiological	O
diagnosis	O
of	O
dementia	B
,	O
electroencephalogram	O
(	O
EEG	O
)	O
and	O
imaging	O
findings	O
,	O
and	O
response	O
to	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
in	O
these	O
individuals	O
.	O

METHODS	O
:	O
A	O
retrospective	O
study	O
was	O
performed	O
identifying	O
patients	O
in	O
the	O
Mayo	O
Alzheimer	B
Disease	I
Patient	O
Registry	O
(	O
ADPR	O
)	O
and	O
Alzheimer	B
Disease	I
Research	O
Center	O
(	O
ADRC	O
)	O
who	O
were	O
classified	O
as	O
having	O
dementia	B
and	O
epilepsy	B
from	O
1986	O
to	O
2006	O
.	O

Multiple	O
clinical	O
parameters	O
were	O
extracted	O
from	O
patient	O
charts	O
and	O
evaluated	O
to	O
characterize	O
the	O
primary	O
neurodegenerative	B
disorder	I
and	O
seizure	B
outcomes	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
three	O
of	O
the	O
1738	O
ADPR	O
and	O
ADRC	O
patients	O
(	O
3.6	O
%	O
)	O
had	O
epilepsy	B
.	O

Twenty	O
-	O
four	O
of	O
the	O
63	O
patients	O
were	O
excluded	O
because	O
of	O
insufficient	O
information	O
regarding	O
their	O
epilepsy	B
.	O

The	O
remaining	O
39	O
patients	O
were	O
analyzed	O
.	O

Twenty	O
-	O
eight	O
of	O
the	O
63	O
patients	O
(	O
72	O
%	O
)	O
experienced	O
complex	B
partial	I
seizures	I
.	O

Head	O
MRI	O
was	O
performed	O
in	O
35	O
patients	O
(	O
90	O
%	O
)	O
.	O

Fourteen	O
patients	O
(	O
36	O
%	O
)	O
had	O
MRI	O
-	O
identified	O
structural	O
lesions	O
that	O
included	O
remote	O
stroke	B
and	O
prior	O
intracerebral	B
hemorrhage	I
.	O

EEGs	O
were	O
obtained	O
in	O
29	O
patients	O
(	O
74	O
%	O
)	O
.	O

Fifteen	O
patients	O
(	O
38	O
%	O
)	O
had	O
epileptiform	O
discharges	O
.	O

Overall	O
,	O
it	O
was	O
found	O
that	O
79	O
%	O
had	O
an	O
excellent	O
response	O
to	O
AED	O
therapy	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
patients	O
had	O
dose	B
-	I
related	I
side	I
effects	I
from	O
an	O
AED	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
indicated	O
that	O
most	O
individuals	O
with	O
the	O
comorbidity	O
of	O
epilepsy	B
and	O
dementia	B
have	O
complex	B
partial	I
seizures	I
that	O
may	O
be	O
adequately	O
controlled	O
on	O
AED	O
therapy	O
.	O

The	O
long	O
-	O
term	O
effect	O
of	O
seizure	B
activity	O
on	O
the	O
neurodegenerative	B
disorder	I
is	O
unknown	O
.	O

Pharmacokinetic	O
-	O
directed	O
dosing	O
of	O
vandetanib	O
and	O
docetaxel	O
in	O
a	O
mouse	O
model	O
of	O
human	O
squamous	B
cell	I
carcinoma	I
.	O

Docetaxel	O
,	O
usually	O
administered	O
according	O
to	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
can	O
inhibit	O
endothelial	O
cell	O
proliferation	O
at	O
low	O
nanomolar	O
concentrations	O
.	O

Docetaxel	O
may	O
exert	O
antiangiogenic	O
effects	O
if	O
dosed	O
so	O
plasma	O
levels	O
are	O
maintained	O
at	O
low	O
nanomolar	O
concentrations	O
over	O
a	O
prolonged	O
time	O
.	O

We	O
evaluated	O
metronomic	O
and	O
MTD	O
-	O
based	O
dosing	O
of	O
docetaxel	O
with	O
and	O
without	O
vandetanib	O
,	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	O
activity	O
,	O
in	O
a	O
head	O
and	O
neck	O
xenograft	O
model	O
.	O

A	O
murine	O
physiologically	O
based	O
pharmacokinetic	O
model	O
was	O
modified	O
to	O
predict	O
docetaxel	O
distribution	O
following	O
i	O
.	O

p	O
.	O

administration	O
to	O
design	O
dosing	O
regimens	O
that	O
target	O
prespecified	O
plasma	O
concentrations	O
,	O
for	O
antiendothelial	O
effects	O
(	O
metronomic	O
)	O
,	O
or	O
exposure	O
,	O
to	O
mimic	O
30	O
mg	O
/	O
m2	O
(	O
weekly	O
/	O
MTD	O
)	O
docetaxel	O
in	O
humans	O
.	O

Animals	O
were	O
treated	O
for	O
28	O
days	O
with	O
1	O
mg	O
/	O
kg	O
/	O
d	O
(	O
DTX1	O
)	O
or	O
6	O
mg	O
/	O
kg	O
q4d	O
(	O
DTX6	O
)	O
docetaxel	O
with	O
or	O
without	O
vandetanib	O
(	O
15	O
mg	O
/	O
kg	O
/	O
d	O
p	O
.	O

o	O
.	O
)	O
in	O
mice	O
bearing	O
UMSCC2	O
tumor	B
xenografts	O
.	O

The	O
DTX1	O
dosing	O
scheme	O
was	O
adjusted	O
to	O
treatment	O
for	O
10	O
days	O
followed	O
by	O
9	O
days	O
off	O
due	O
to	O
severe	O
gastrointestinal	B
toxicity	I
.	O

All	O
treatment	O
groups	O
significantly	O
reduced	O
tumor	B
volume	O
,	O
tumor	B
proliferation	O
(	O
Ki	O
-	O
67	O
)	O
,	O
and	O
tumor	O
endothelial	O
cell	O
proliferation	O
(	O
Ki	O
-	O
67	O
/	O
von	O
Willebrand	O
factor	O
)	O
compared	O
with	O
control	O
.	O

Addition	O
of	O
vandetanib	O
to	O
docetaxel	O
treatment	O
significantly	O
enhanced	O
tumor	B
growth	O
inhibition	O
over	O
single	O
-	O
agent	O
therapy	O
.	O

A	O
positive	O
correlation	O
of	O
tumor	O
endothelial	O
cell	O
proliferation	O
with	O
tumor	B
growth	O
rates	O
demonstrates	O
vandetanib	O
and	O
docetaxel	O
antiangiogenic	O
effects	O
.	O

Due	O
to	O
the	O
morbidity	O
observed	O
with	O
DTX1	O
treatment	O
,	O
it	O
is	O
difficult	O
to	O
clearly	O
ascertain	O
if	O
metronomic	O
schedules	O
will	O
be	O
effective	O
for	O
treatment	O
.	O

Docetaxel	O
with	O
vandetanib	O
is	O
effective	O
in	O
treating	O
UMSCC2	O
xenografts	O
at	O
concentrations	O
relevant	O
to	O
exposures	O
in	O
humans	O
.	O

Prospective	O
evaluation	O
of	O
sexual	O
function	O
in	O
patients	O
receiving	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
prospectively	O
the	O
sexual	O
function	O
of	O
patients	O
undergoing	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
,	O
as	O
the	O
development	O
of	O
17	O
G	O
cryotherapy	O
probes	O
has	O
improved	O
the	O
delivery	O
of	O
this	O
treatment	O
,	O
but	O
one	O
of	O
the	O
side	O
-	O
effects	O
of	O
cryosurgery	O
is	O
the	O
development	O
of	O
erectile	B
dysfunction	I
(	O
ED	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
July	O
2003	O
and	O
May	O
2008	O
,	O
53	O
patients	O
were	O
treated	O
using	O
an	O
argon	O
-	O
based	O
third	O
-	O
generation	O
cryotherapy	O
system	O
(	O
Oncura	O
,	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Prospective	O
data	O
were	O
collected	O
at	O
6	O
weeks	O
,	O
3	O
months	O
,	O
then	O
3	O
-	O
monthly	O
up	O
to	O
1	O
year	O
and	O
subsequently	O
6	O
-	O
monthly	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
up	O
to	O
54	O
months	O
,	O
with	O
a	O
median	O
(	O
mean	O
)	O
follow	O
-	O
up	O
36	O
(	O
30.5	O
)	O
months	O
.	O

RESULTS	O
:	O
All	O
53	O
patients	O
were	O
followed	O
after	O
receiving	O
cryosurgery	O
as	O
primary	O
treatment	O
for	O
prostate	B
cancer	I
;	O
51	O
(	O
96.3	O
%	O
)	O
had	O
ED	O
at	O
6	O
weeks	O
while	O
two	O
(	O
3.7	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
9	O
months	O
one	O
(	O
2.4	O
%	O
)	O
of	O
42	O
patients	O
was	O
fully	O
potent	O
using	O
phosphodiesterase	O
type	O
-	O
5	O
inhibitors	O
,	O
and	O
six	O
(	O
14.3	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
18	O
months	O
eight	O
(	O
21	O
%	O
)	O
of	O
39	O
patients	O
followed	O
up	O
had	O
regained	O
full	O
potency	O
and	O
by	O
24	O
months	O
eight	O
(	O
24	O
%	O
)	O
of	O
33	O
patients	O
were	O
fully	O
potent	O
and	O
three	O
(	O
9	O
%	O
)	O
experienced	O
partial	O
erections	O
.	O

CONCLUSION	O
:	O
While	O
ED	B
is	O
a	O
significant	O
side	O
-	O
effect	O
of	O
cryotherapy	O
,	O
a	O
considerable	O
proportion	O
of	O
patients	O
who	O
have	O
no	O
ED	B
before	O
treatment	O
(	O
39	O
%	O
)	O
recover	O
full	O
sexual	O
function	O
afterward	O
.	O

Focal	O
nerve	O
-	O
sparing	O
cryosurgery	O
might	O
be	O
the	O
way	O
forward	O
in	O
an	O
attempt	O
to	O
preserve	O
erectile	O
function	O
in	O
men	O
who	O
had	O
no	O
ED	B
before	O
treatment	O
.	O

Erectile	O
aids	O
should	O
be	O
made	O
available	O
for	O
those	O
patients	O
for	O
whom	O
sexual	B
dysfunction	I
compromises	O
the	O
quality	O
of	O
their	O
life	O
and	O
relationships	O
.	O

A	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
raises	O
platelet	O
count	O
as	O
efficiently	O
as	O
intravenous	O
immunoglobulin	O
in	O
newly	O
diagnosed	O
immune	B
thrombocytopenic	I
purpura	I
in	O
Korean	O
children	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
(	O
anti	O
-	O
D	O
)	O
at	O
50	O
mug	O
/	O
kg	O
to	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
in	O
Korean	O
children	O
with	O
acute	B
immune	I
thrombocytopenic	I
purpura	I
(	O
ITP	B
)	O
.	O

METHODS	O
:	O
We	O
performed	O
this	O
study	O
prospectively	O
by	O
randomly	O
administering	O
2	O
consecutive	O
doses	O
of	O
IVIG	O
at	O
a	O
dose	O
of	O
1.0	O
g	O
/	O
kg	O
/	O
dor	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
at	O
50	O
microg	O
/	O
kg	O
to	O
children	O
upon	O
initial	O
diagnosis	O
of	O
acute	B
ITP	I
.	O

The	O
platelet	O
count	O
and	O
adverse	O
events	O
,	O
including	O
hemoglobin	O
concentration	O
,	O
were	O
then	O
serially	O
evaluated	O
,	O
and	O
the	O
responses	O
were	O
compared	O
.	O

RESULTS	O
:	O
The	O
likelihood	O
of	O
having	O
a	O
platelet	O
count	O
greater	O
than	O
20x10	O
/	O
mm	O
after	O
3	O
days	O
of	O
treatment	O
in	O
the	O
IVIG	O
and	O
anti	O
-	O
D	O
group	O
was	O
93	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
hemoglobin	O
concentration	O
in	O
the	O
anti	O
-	O
D	O
group	O
had	O
declined	O
more	O
than	O
that	O
of	O
the	O
IVIG	O
group	O
(	O
1.49	O
g	O
/	O
dL	O
vs.	O
0.80	O
g	O
/	O
dL	O
,	O
P	O
=	O
0.014	O
)	O
3	O
days	O
after	O
treatment	O
.	O

Fever	B
,	O
chills	B
,	O
and	O
headache	B
occurred	O
less	O
frequently	O
in	O
the	O
anti	O
-	O
D	O
group	O
than	O
the	O
IVIG	O
group	O
,	O
however	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
25	O
%	O
vs.	O
45	O
%	O
,	O
P	O
=	O
0.494	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
single	O
dose	O
of	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
raised	O
platelet	O
count	O
as	O
efficiently	O
as	O
IVIG	O
in	O
newly	O
diagnosed	O
cases	O
of	O
ITP	B
in	O
Korean	O
children	O
.	O

Although	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
had	O
a	O
greater	O
effect	O
on	O
the	O
hemoglobin	O
concentration	O
than	O
IVIG	O
,	O
the	O
adverse	O
effects	O
were	O
found	O
to	O
be	O
acceptable	O
,	O
and	O
no	O
serious	O
events	O
were	O
observed	O
.	O

Right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
in	O
humans	O
:	O
an	O
effective	O
therapy	O
?	O

Vagus	O
nerve	O
stimulation	O
(	O
VNS	O
)	O
is	O
an	O
additive	O
treatment	O
option	O
for	O
refractory	B
epilepsy	I
.	O

The	O
electrode	O
is	O
placed	O
on	O
the	O
cervical	O
trunk	O
of	O
the	O
left	O
vagus	O
nerve	O
.	O

In	O
patients	O
who	O
are	O
not	O
suitable	O
for	O
left	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
L	O
-	O
VNS	O
)	O
right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
R	O
-	O
VNS	O
)	O
may	O
be	O
as	O
effective	O
.	O

In	O
animal	O
models	O
epilepsy	B
is	O
sufficiently	O
suppressed	O
by	O
R	O
-	O
VNS	O
.	O

In	O
a	O
16	O
years	O
old	O
boy	O
suffering	O
from	O
medically	O
refractory	B
psychomotoric	I
seizures	I
with	O
secondary	O
generalisation	O
,	O
L	O
-	O
VNS	O
reduced	O
the	O
frequency	O
of	O
generalized	O
seizures	B
.	O

A	O
deep	O
wound	B
infection	I
required	O
the	O
removal	O
of	O
the	O
system	O
eight	O
weeks	O
later	O
.	O

Cicatrisation	O
did	O
not	O
allow	O
preparation	O
of	O
the	O
left	O
vagus	O
nerve	O
,	O
therefore	O
we	O
implanted	O
R	O
-	O
VNS	O
with	O
sufficient	O
seizure	B
suppression	O
.	O

However	O
,	O
compared	O
to	O
L	O
-	O
VNS	O
,	O
the	O
effect	O
occurred	O
months	O
later	O
and	O
cardiac	B
symptoms	I
were	O
induced	O
by	O
stimulation	O
of	O
the	O
right	O
vagus	O
nerve	O
.	O

R	O
-	O
VNS	O
seems	O
to	O
be	O
an	O
effective	O
and	O
alternative	O
therapy	O
in	O
selected	O
patients	O
responding	O
to	O
L	O
-	O
VNS	O
where	O
a	O
left	O
-	O
sided	O
reimplantation	O
is	O
not	O
possible	O
.	O

Placement	O
and	O
adjustment	O
of	O
the	O
device	O
should	O
be	O
performed	O
under	O
ECG	O
control	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
compare	O
the	O
efficacy	O
of	O
L	O
-	O
VNS	O
and	O
R	O
-	O
VNS	O
.	O

Astaxanthin	O
,	O
canthaxanthin	O
and	O
beta	O
-	O
carotene	O
differently	O
affect	O
UVA	O
-	O
induced	O
oxidative	O
damage	O
and	O
expression	O
of	O
oxidative	O
stress	O
-	O
responsive	O
enzymes	O
.	O

Carotenoids	O
are	O
used	O
for	O
systemic	O
photoprotection	O
in	O
humans	O
.	O

Regarding	O
mechanisms	O
underlying	O
photoprotective	O
effects	O
of	O
carotenoids	O
,	O
here	O
we	O
compared	O
the	O
modulation	O
of	O
UVA	O
-	O
related	O
injury	O
by	O
carotenoids	O
.	O

Human	O
dermal	O
fibroblasts	O
(	O
HDF	O
)	O
were	O
exposed	O
to	O
moderate	O
doses	O
of	O
UVA	O
,	O
which	O
stimulated	O
apoptosis	O
,	O
increased	O
levels	O
of	O
reactive	O
oxygen	O
species	O
and	O
thiobarbituric	O
acid	O
reactive	O
substances	O
,	O
decreased	O
antioxidant	O
enzymes	O
activities	O
,	O
promoted	O
membrane	O
perturbation	O
,	O
and	O
induced	O
the	O
expression	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
.	O

The	O
carotenoids	O
astaxanthin	O
(	O
AX	O
)	O
,	O
canthaxanthin	O
(	O
CX	O
)	O
and	O
beta	O
-	O
carotene	O
(	O
betaC	O
)	O
were	O
delivered	O
to	O
HDF	O
24	O
h	O
before	O
exposure	O
to	O
UVA	O
.	O

Astaxanthin	O
exhibited	O
a	O
pronounced	O
photoprotective	O
effect	O
and	O
counteracted	O
all	O
of	O
the	O
above	O
-	O
mentioned	O
UVA	O
-	O
induced	O
alterations	O
to	O
a	O
significant	O
extent	O
.	O

beta	O
-	O
Carotene	O
only	O
partially	O
prevented	O
the	O
UVA	O
-	O
induced	O
decline	O
of	O
catalase	O
and	O
superoxide	O
dismutase	O
activities	O
,	O
but	O
it	O
increased	O
membrane	O
damage	O
and	O
stimulated	O
HO	O
-	O
1	O
expression	O
.	O

Moreover	O
,	O
betaC	O
dose	O
-	O
dependently	O
induced	O
caspase	O
-	O
3	O
activity	O
following	O
UVA	O
exposure	O
.	O

In	O
contrast	O
,	O
CX	O
had	O
no	O
effect	O
on	O
oxidative	O
damage	O
,	O
except	O
for	O
HO	O
-	O
1	O
expression	O
,	O
which	O
was	O
augmented	O
.	O

Uptake	O
of	O
AX	O
by	O
fibroblasts	O
was	O
higher	O
than	O
that	O
of	O
the	O
other	O
two	O
carotenoids	O
.	O

The	O
photostability	O
of	O
the	O
three	O
compounds	O
in	O
fibroblasts	O
was	O
AX	O
>	O
CX	O
>	O
>	O
betaC	O
.	O

The	O
data	O
indicate	O
that	O
the	O
oxo	O
-	O
carotenoid	O
AX	O
has	O
a	O
superior	O
preventive	O
effect	O
towards	O
photo	O
-	O
oxidative	O
changes	O
in	O
cell	O
culture	O
.	O

Protective	O
effect	O
of	O
Pycnogenol	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
following	O
acrolein	O
-	O
induced	O
cytotoxicity	B
.	O

Oxidative	O
stress	O
is	O
one	O
of	O
the	O
hypotheses	O
involved	O
in	O
the	O
etiology	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Considerable	O
attention	O
has	O
been	O
focused	O
on	O
increasing	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
many	O
neurodegenerative	B
diseases	I
,	O
including	O
AD	B
.	O

Pycnogenol	O
(	O
PYC	O
)	O
has	O
antioxidant	O
properties	O
and	O
stabilizes	O
intracellular	O
antioxidant	O
defense	O
systems	O
including	O
glutathione	O
levels	O
.	O

The	O
present	O
study	O
investigated	O
the	O
protective	O
effects	O
of	O
PYC	O
on	O
acrolein	O
-	O
induced	O
oxidative	B
cell	I
toxicity	I
in	O
cultured	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Decreased	O
cell	O
survival	O
in	O
SH	O
-	O
SY5Y	O
cultures	O
treated	O
with	O
acrolein	O
correlated	O
with	O
oxidative	O
stress	O
,	O
increased	O
NADPH	O
oxidase	O
activity	O
,	O
free	O
radical	O
production	O
,	O
protein	O
oxidation	O
/	O
nitration	O
(	O
protein	O
carbonyl	O
,	O
3	O
-	O
nitrotyrosine	O
)	O
,	O
and	O
lipid	O
peroxidation	O
(	O
4	O
-	O
hydroxy	O
-	O
2	O
-	O
nonenal	O
)	O
.	O

Pretreatment	O
with	O
PYC	O
significantly	O
attenuated	O
acrolein	O
-	O
induced	O
cytotoxicity	B
,	O
protein	O
damage	O
,	O
lipid	O
peroxidation	O
,	O
and	O
cell	O
death	O
.	O

A	O
dose	O
-	O
response	O
study	O
suggested	O
that	O
PYC	O
showed	O
protective	O
effects	O
against	O
acrolein	B
toxicity	I
by	O
modulating	O
oxidative	O
stress	O
and	O
increasing	O
GSH	O
.	O

These	O
findings	O
provide	O
support	O
that	O
PYC	O
may	O
provide	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
oxidative	O
stress	O
-	O
related	O
neurodegenerative	B
diseases	I
such	O
as	O
AD	B
.	O

Lipid	O
nanoparticles	O
for	O
parenteral	O
delivery	O
of	O
actives	O
.	O

The	O
present	O
review	O
compiles	O
the	O
applications	O
of	O
lipid	O
nanoparticles	O
mainly	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
,	O
nanostructured	O
lipid	O
carriers	O
(	O
NLC	O
)	O
and	O
lipid	O
drug	O
conjugates	O
(	O
LDC	O
)	O
in	O
parenteral	O
delivery	O
of	O
pharmaceutical	O
actives	O
.	O

The	O
attempts	O
to	O
incorporate	O
anticancer	O
agents	O
,	O
imaging	O
agents	O
,	O
antiparasitics	O
,	O
antiarthritics	O
,	O
genes	O
for	O
transfection	O
,	O
agents	O
for	O
liver	O
,	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
targeting	O
have	O
been	O
summarized	O
.	O

The	O
utility	O
of	O
lipid	O
nanoparticles	O
as	O
adjuvant	O
has	O
been	O
discussed	O
separately	O
.	O

A	O
special	O
focus	O
of	O
this	O
review	O
is	O
on	O
toxicity	O
caused	O
by	O
these	O
kinds	O
of	O
lipid	O
nanoparticles	O
with	O
a	O
glance	O
on	O
the	O
fate	O
of	O
lipid	O
nanoparticles	O
after	O
their	O
parenteral	O
delivery	O
in	O
vivo	O
viz	O
the	O
protein	O
adsorption	O
patterns	O
.	O

Orally	O
administrated	O
Juzen	O
-	O
taiho	O
-	O
to	O
/	O
TJ	O
-	O
48	O
ameliorates	O
erythropoietin	B
(	I
rHuEPO	I
)	I
-	I
resistant	I
anemia	I
in	O
patients	O
on	O
hemodialysis	O
.	O

Maintenance	O
of	O
the	O
red	O
blood	O
cell	O
volume	O
is	O
a	O
fundamental	O
aspect	O
of	O
ensuring	O
oxygen	O
supply	O
to	O
the	O
tissue	O
.	O

Recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
was	O
approved	O
for	O
marketing	O
in	O
Japan	O
in	O
1990	O
for	O
the	O
treatment	O
of	O
anemia	B
in	O
patients	O
on	O
dialysis	O
.	O

Recombinant	O
human	O
erythropoietin	O
caused	O
a	O
significant	O
increase	O
in	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
in	O
patients	O
on	O
dialysis	O
.	O

However	O
,	O
not	O
all	O
have	O
a	O
good	O
response	O
to	O
rHuEPO	O
therapy	O
;	O
the	O
causes	O
of	O
rHuEPO	O
failure	O
include	O
iron	B
deficiency	I
,	O
infection	B
,	O
uremia	B
,	O
and	O
interaction	O
of	O
some	O
drugs	O
.	O

Juzen	O
-	O
taiho	O
-	O
to	O
(	O
TJ	O
-	O
48	O
)	O
,	O
a	O
mixture	O
of	O
extracts	O
from	O
10	O
medicinal	O
herbs	O
,	O
has	O
been	O
used	O
traditionally	O
to	O
treat	O
patients	O
with	O
anemia	B
,	O
anorexia	B
,	O
or	O
fatigue	B
.	O

To	O
clarify	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
on	O
erythropoietin	B
-	I
resistant	I
anemia	I
,	O
we	O
studied	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
.	O

We	O
divided	O
42	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
(	O
Hb	O
<	O
10.0	O
g	O
/	O
dL	O
with	O
rHuEPO	O
9000	O
U	O
/	O
wk	O
or	O
15	O
U	O
/	O
kg	O
/	O
wk	O
treatment	O
)	O
into	O
2	O
groups	O
as	O
follows	O
:	O
a	O
TJ	O
-	O
48	O
-	O
treated	O
group	O
(	O
TJ	O
-	O
48	O
group	O
,	O
7.5	O
g	O
/	O
d	O
,	O
n	O
=	O
22	O
)	O
and	O
a	O
TJ	O
-	O
48	O
nontreated	O
(	O
control	O
group	O
,	O
n	O
=	O
20	O
)	O
.	O

At	O
the	O
beginning	O
of	O
this	O
study	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
in	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
,	O
serum	O
iron	O
,	O
and	O
ferritin	O
.	O

After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
Hb	O
level	O
had	O
significantly	O
increased	O
from	O
8.4	O
+	O
/	O
-	O
1.1	O
to	O
9.5	O
+	O
/	O
-	O
1.3	O
g	O
/	O
dL	O
(	O
P	O
=	O
0.0272	O
)	O
in	O
the	O
TJ	O
-	O
48	O
group	O
.	O

C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
had	O
significantly	O
decreased	O
from	O
1.4	O
+	O
/	O
-	O
1.7	O
to	O
0.6	O
+	O
/	O
-	O
0.8	O
mg	O
/	O
dL	O
(	O
P	O
=	O
0.0438	O
)	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
TJ	O
-	O
48	O
group	O
(	O
r	O
(	O
2	O
)	O
=	O
0.121	O
,	O
P	O
=	O
0.0066	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
control	O
group	O
,	O
Hb	O
and	O
CRP	O
showed	O
no	O
significant	O
changes	O
throughout	O
this	O
study	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
TJ	O
-	O
48	O
was	O
effective	O
in	O
improving	O
erythropoietin	B
-	I
resistant	I
anemia	I
in	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
.	O

This	O
effect	O
was	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
.	O

Fragrance	O
material	O
review	O
on	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Vitamin	O
K	O
supplementation	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
(	O
ECKO	O
trial	O
)	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
:	O
Vitamin	O
K	O
has	O
been	O
widely	O
promoted	O
as	O
a	O
supplement	O
for	O
decreasing	O
bone	B
loss	I
in	O
postmenopausal	O
women	O
,	O
but	O
the	O
long	O
-	O
term	O
benefits	O
and	O
potential	O
harms	O
are	O
unknown	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
whether	O
daily	O
high	O
-	O
dose	O
vitamin	O
K1	O
supplementation	O
safely	O
reduces	O
bone	B
loss	I
,	O
bone	O
turnover	O
,	O
and	O
fractures	O
.	O

METHODS	O
AND	O
FINDINGS	O
:	O
This	O
single	O
-	O
center	O
study	O
was	O
designed	O
as	O
a	O
2	O
-	O
y	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
,	O
extended	O
for	O
earlier	O
participants	O
for	O
up	O
to	O
an	O
additional	O
2	O
y	O
because	O
of	O
interest	O
in	O
long	O
-	O
term	O
safety	O
and	O
fractures	O
.	O

A	O
total	O
of	O
440	O
postmenopausal	O
women	O
with	O
osteopenia	B
were	O
randomized	O
to	O
either	O
5	O
mg	O
of	O
vitamin	O
K1	O
or	O
placebo	O
daily	O
.	O

Primary	O
outcomes	O
were	O
changes	O
in	O
BMD	O
at	O
the	O
lumbar	O
spine	O
and	O
total	O
hip	O
at	O
2	O
y	O
.	O

Secondary	O
outcomes	O
included	O
changes	O
in	O
BMD	O
at	O
other	O
sites	O
and	O
other	O
time	O
points	O
,	O
bone	O
turnover	O
markers	O
,	O
height	O
,	O
fractures	O
,	O
adverse	O
effects	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

This	O
study	O
has	O
a	O
power	O
of	O
90	O
%	O
to	O
detect	O
3	O
%	O
differences	O
in	O
BMD	O
between	O
the	O
two	O
groups	O
.	O

The	O
women	O
in	O
this	O
study	O
were	O
vitamin	O
D	O
replete	O
,	O
with	O
a	O
mean	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
level	O
of	O
77	O
nmol	O
/	O
l	O
at	O
baseline	O
.	O

Over	O
2	O
y	O
,	O
BMD	O
decreased	O
by	O
-	O
1.28	O
%	O
and	O
-	O
1.22	O
%	O
(	O
p	O
=	O
0.84	O
)	O
(	O
difference	O
of	O
-	O
0.06	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
0.67	O
%	O
to	O
0.54	O
%	O
)	O
at	O
the	O
lumbar	O
spine	O
and	O
-	O
0.69	O
%	O
and	O
-	O
0.88	O
%	O
(	O
p	O
=	O
0.51	O
)	O
(	O
difference	O
of	O
0.19	O
%	O
;	O
95	O
%	O
CI	O
-	O
0.37	O
%	O
to	O
0.75	O
%	O
)	O
at	O
the	O
total	O
hip	O
in	O
the	O
vitamin	O
K	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
changes	O
in	O
BMD	O
at	O
any	O
site	O
between	O
the	O
two	O
groups	O
over	O
the	O
2	O
-	O
to	O
4	O
-	O
y	O
period	O
.	O

Daily	O
vitamin	O
K1	O
supplementation	O
increased	O
serum	O
vitamin	O
K1	O
levels	O
by	O
10	O
-	O
fold	O
,	O
and	O
decreased	O
the	O
percentage	O
of	O
undercarboxylated	O
osteocalcin	O
and	O
total	O
osteocalcin	O
levels	O
(	O
bone	O
formation	O
marker	O
)	O
.	O

However	O
,	O
C	O
-	O
telopeptide	O
levels	O
(	O
bone	O
resorption	O
marker	O
)	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Fewer	O
women	O
in	O
the	O
vitamin	O
K	O
group	O
had	O
clinical	O
fractures	O
(	O
nine	O
versus	O
20	O
,	O
p	O
=	O
0.04	O
)	O
and	O
fewer	O
had	O
cancers	O
(	O
three	O
versus	O
12	O
,	O
p	O
=	O
0.02	O
)	O
.	O

Vitamin	O
K	O
supplements	O
were	O
well	O
-	O
tolerated	O
over	O
the	O
4	O
-	O
y	O
period	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
adverse	O
effects	O
or	O
health	O
-	O
related	O
quality	O
of	O
life	O
between	O
the	O
two	O
groups	O
.	O

The	O
study	O
was	O
not	O
powered	O
to	O
examine	O
fractures	O
or	O
cancers	O
,	O
and	O
their	O
numbers	O
were	O
small	O
.	O

CONCLUSIONS	O
:	O
Daily	O
5	O
mg	O
of	O
vitamin	O
K1	O
supplementation	O
for	O
2	O
to	O
4	O
y	O
does	O
not	O
protect	O
against	O
age	O
-	O
related	O
decline	O
in	O
BMD	O
,	O
but	O
may	O
protect	O
against	O
fractures	O
and	O
cancers	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
.	O

More	O
studies	O
are	O
needed	O
to	O
further	O
examine	O
the	O
effect	O
of	O
vitamin	O
K	O
on	O
fractures	O
and	O
cancers	O
.	O

Trial	O
registration	O
:	O
ClinicalTrials	O
.	O

gov	O
(	O
#	O
NCT00150969	O
)	O
and	O
Current	O
Controlled	O
Trials	O
(	O
#	O
ISRCTN61708241	O
)	O
.	O

Peptide	O
-	O
mediated	O
cellular	O
uptake	O
of	O
cryptophane	O
.	O

Cryptophane	O
-	O
A	O
has	O
generated	O
considerable	O
interest	O
based	O
on	O
its	O
high	O
affinity	O
for	O
xenon	O
and	O
potential	O
for	O
creating	O
biosensors	O
for	O
(	O
129	O
)	O
Xe	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
.	O

Here	O
,	O
we	O
report	O
the	O
cellular	O
delivery	O
of	O
three	O
peptide	O
-	O
functionalized	O
cryptophane	O
biosensors	O
.	O

Cryptophanes	O
were	O
delivered	O
using	O
two	O
cationic	O
cell	O
penetrating	O
peptides	O
into	O
several	O
human	O
cancer	B
and	O
normal	O
cell	O
lines	O
.	O

An	O
RGD	O
peptide	O
targeting	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
receptor	O
was	O
shown	O
to	O
increase	O
specificity	O
of	O
cryptophane	O
cell	O
uptake	O
.	O

Labeling	O
the	O
peptides	O
with	O
Cy3	O
made	O
it	O
possible	O
to	O
monitor	O
cellular	O
delivery	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

The	O
peptido	O
-	O
cryptophanes	O
were	O
determined	O
to	O
be	O
relatively	O
nontoxic	O
by	O
MTT	O
assay	O
at	O
the	O
micromolar	O
cryptophane	O
concentrations	O
that	O
are	O
required	O
for	O
(	O
129	O
)	O
Xe	O
NMR	O
biosensing	O
experiments	O
.	O

Effectiveness	O
and	O
tolerability	O
of	O
open	O
label	O
olanzapine	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
.	O

OBJECTIVES	O
:	O
The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
open	O
-	O
label	O
olanzapine	O
on	O
motor	O
and	O
vocal	O
tics	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
.	O

Secondary	O
aims	O
included	O
assessing	O
the	O
response	O
of	O
TS	O
-	O
associated	O
disruptive	B
behaviors	I
to	O
olanzapine	O
exposure	O
.	O

METHOD	O
:	O
Twelve	O
children	O
and	O
adolescents	O
(	O
mean	O
age	O
11.3	O
+	O
/	O
-	O
2.4	O
years	O
,	O
range	O
7	O
-	O
14	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B
Disorders	I
,	O
4th	O
edition	O
(	O
DSM	O
-	O
IV	O
)	O
TS	B
were	O
enrolled	O
in	O
a	O
single	O
-	O
site	O
,	O
6	O
-	O
week	O
,	O
open	O
-	O
label	O
,	O
prospective	O
,	O
flexible	O
-	O
dose	O
design	O
in	O
outpatients	O
receiving	O
monotherapy	O
with	O
olanzapine	O
.	O

Standardized	O
ratings	O
of	O
tic	B
symptoms	I
,	O
disruptive	B
behaviors	I
,	O
and	O
aggression	B
were	O
obtained	O
,	O
along	O
with	O
adverse	O
events	O
and	O
safety	O
data	O
.	O

RESULTS	O
:	O
Over	O
the	O
6	O
-	O
week	O
trial	O
,	O
olanzapine	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
total	O
tic	B
severity	O
as	O
measured	O
by	O
the	O
Yale	O
Global	O
Tic	B
Severity	O
Scale	O
(	O
30	O
%	O
reduction	O
by	O
week	O
6	O
;	O
effect	O
size	O
0.49	O
)	O
.	O

A	O
significant	O
majority	O
of	O
subjects	O
were	O
rated	O
as	O
""""	O
much	O
improved	O
""""	O
or	O
""""	O
very	O
much	O
improved	O
""""	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
-	O
Improvement	O
Scale	O
(	O
GCI	O
-	O
I	O
)	O
by	O
both	O
clinicians	O
(	O
67	O
%	O
;	O
8	O
/	O
12	O
)	O
and	O
parents	O
(	O
64	O
%	O
;	O
7	O
/	O
11	O
)	O
.	O

Attention	B
-	I
deficit	I
/	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
symptoms	O
showed	O
significant	O
improvements	O
from	O
baseline	O
for	O
both	O
inattention	O
(	O
33	O
%	O
decrease	O
)	O
and	O
hyperactive	O
/	O
impulsivity	O
(	O
50	O
%	O
decrease	O
)	O
scores	O
(	O
effect	O
sizes	O
0.44	O
and	O
0.43	O
,	O
respectively	O
)	O
.	O

Aggression	B
was	O
also	O
decreased	O
as	O
assessed	O
by	O
fewer	O
numbers	O
of	O
aggressive	O
episodes	O
on	O
the	O
Overt	O
Aggression	B
Scale	O
(	O
OAS	O
)	O
.	O

Little	O
change	O
in	O
anxiety	B
symptoms	O
was	O
noted	O
.	O

The	O
most	O
widely	O
reported	O
side	O
effects	O
were	O
drowsiness	B
/	O
sedation	B
and	O
weight	O
gain	O
;	O
adverse	O
events	O
were	O
generally	O
well	O
tolerated	O
.	O

Mean	O
weight	O
gain	O
of	O
4.1	O
+	O
/	O
-	O
2.0	O
kg	O
was	O
observed	O
over	O
the	O
6	O
-	O
week	O
trial	O
,	O
a	O
mean	O
percent	O
change	O
of	O
8.4	O
+	O
/	O
-	O
4.4	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Additional	O
studies	O
of	O
the	O
benefits	O
of	O
olanzapine	O
treatment	O
for	O
tic	B
control	O
as	O
well	O
as	O
the	O
commonly	O
associated	O
co	O
-	O
morbid	O
features	O
of	O
TS	B
are	O
indicated	O
,	O
especially	O
if	O
approaches	O
to	O
predict	O
or	O
minimize	O
weight	O
gain	O
can	O
be	O
determined	O
.	O

